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Abstract: 
Vinylogous Esters and Amides: Useful Synthons for Diversity-Oriented and 
Natural Product Synthesis 
 
Matthew W. Leighty 
The University of Kansas, 2009 
 
The first total synthesis of boehmeriasin A was achieved in seven steps from 
readily available materials with an overall yield of 29%.  The absolute 
stereochemistry of the natural product was determined to be of the (R)-configuration. 
(-)-(R)-Boehmeriasin A demonstrated potent cytotoxicity in several cancer cell lines 
including drug resistant cancer cells where paclitaxel is inactive.  
An efficient and mild method for the construction if chromones was 
developed that requires only a single purification step at the end of the sequence and 
results in moderate to good yields of the isolated chromones. This method was 
applied toward the synthesis of 5-hydroxy-2-(2-phenylethyl)chromone, a 
neuroprotective chromone. 
The reduction of tertiary amides using Cp2Zr(H)Cl to the corresponding 
aldehydes on a preparatory scale results in good isolated yields of the products. 
Through a modified workup procedure, issues not previously observed were 
overcome to afford good isolated yields of the corresponding aldehydes. 
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Chapter 1 
Total Synthesis, Absolute Stereochemistry Determination, and Initial Biological 
Evaluation of Boehmeriasin A 
 
1.1 Background 
Natural products continue to be valuable sources of biologically active 
molecules that can serve as lead compounds for further development.1 Examples of 
anticancer natural products that have inspired compounds on the market include the 
epothilones, taxanes, and Vinca alkaloids.2 Phenanthroindolizidine and the less 
prevalent phenanthroquinolizidine alkaloids also have prominent anticancer profiles.3-
23 These alkaloids demonstrate other pharmacological activities including 
antiinflammmatory,24-29 antimicrobial,16 and antiviral activities28,29 as well.  Since the 
isolation of the first phenanthroindolizidine tylophorine in 1935,30 this class of natural 
products has attracted the attention of the synthetic community due to their unique 
architecture and impressive biological activity that has culminated in several total 
syntheses of these alkaloids.12  
Boehmeriasin A and B were recently isolated from the aqueous ethanolic 
extract of Boehmeria siamensis Craib (Utricaceae) through a bioassay-guided 
fractionation investigation (Figure 1).13 The structures of these 
phenanthroquinolizidine alkaloids were determined through spectral evidence.  
However, the absolute stereochemistry of either alkaloid was not determined.  Both 
alkaloids were evaluated against a panel of twelve different cancer cell lines for 
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cytotoxic activity that included leukemia and cancers of the lung, colon, breast, 
prostate, and kidney. Boehmeriasin A was found to be more potent than paclitaxel 
and boehmeriasin B in most cell lines evaluated with GI50 values ranging from 0.80 to 
265 nM.  Boehmeriasin A potently inhibits the proliferation of breast cancer cell line 
MDA-MB-231 through G1 cell cycle arrest and differentiation induction.31   The 
natural product caused decreased expression levels of cyclin D1 and cyclin E1, 
changes in cell morphology, increased lipid droplet accumulation, and elevated 
expression of adipocyte differentiation-related protein in these cells.   This may be of 
clinical relevance as cyclin D1 is amplified and/or overexpressed in many different 
types of cancer32 and is associated with poor prognosis and chemoresistance.33 
Interestingly, very few apoptotic cells were detected when the cells were treated with 
this natural product.  However, boehmeriasin A’s molecular target(s) responsible for 
its cytotoxicity have not been elucidated. The reported biological activity combined 
with the Georg group’s previous interest in this class of natural products34 made 
boehmeriasin A an attractive target for a total synthesis.  Herein, the first total 
synthesis of this natural product, determination of its absolute stereochemistry, and 
initial anticancer activity is reported. 
N
RO
MeO
OMe
R = Me; boehmeriasin A (1)
R = H; boehmeriasin B (2)
Figure 1.  Structures of Boehmeriasin A and B.  
 19 
Since the last comprehensive review of the phenanthroindolizidine and 
phenanthroquinolizidine alkaloids, more than twenty new phenanthroindolizidine and 
phenanthroquinolizidine alkaloids have been isolated and several total syntheses of 
these natural products have appeared in the literature.12 Although these synthetic 
endeavors employed novel reactions during the course of the synthesis, typical 
construction of the alkaloids follows two general strategies.  The first strategy 
involves assembly of the phenanthrene portion of the molecule first followed by 
synthesis of the aliphatic section of the molecule.  The second commonly employed 
strategy assembles of the indolizidine or quinolizidine prior to construction of the 
aromatic ring system.  Of these two general methods, five common synthetic 
approaches in their respective syntheses of the alkaloids have been used (Scheme 1).  
Where assembly of the phenanthrene core is carried out first the aliphatic core is 
commonly prepared through a Pictect-Spengler reaction, Friedel-Crafts acylation, or 
Diels-Alder reaction.  When the indolizidine or quinolizidine scaffold was prepared 
prior to the phenanthrene moiety, an aldol reaction to assemble ring D followed by an 
intramolecular bi-aryl coupling reaction has been used.  Alternatively, upon 
successful construction of the aliphatic core, palladium-mediated cross-coupling 
reactions have been used to install rings A and C followed by an oxidative coupling 
to afford the desired natural products. 
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A frequently used strategy involves synthesizing the phenanthrene ring (rings 
A-C) with the required substitution pattern for the alkaloid of interest and then 
forming the indolizidine or quinolizidine portion through a Pictet-Spengler reaction. 
This approach is exemplified by a synthetic route developed by Fürstner and co-
workers (Scheme 2).35 As an example of this approach, the synthesis of (±)-
cryptopleurine (8) is shown in Scheme 2.  Using conditions developed in the same 
laboratories, alkyne 3 was treated with nBuLi and 9-MeO-9-BBN to afford 
intermediate 4 that was subsequently coupled with aryliodide 5 to give the key bi-aryl 
intermediate 6. Compound 6 next underwent a PtCl2-catalyzed cycloisomerization to 
afford the desired phenanthrene 7 in 97% yield.  The synthesis of  (±)-cryptopleurine 
(8) was accomplished under a tandem deprotection/Pictect-Spengler reaction 
sequence to afford the natural product in good yield.  The same authors also applied 
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this route to the asymmetric synthesis of the indolizidine alkaloids (-)-antofine, (-)-
tylophorine, and (-)-ficuseptine C, respectively, utilizing D-N-Boc-prolinol as the 
starting material.35 
N
Boc
N
BocB
MeO
Li I
MeO
MeO
OMe
+
MeO
MeO
OMe
N
Boc
MeO
MeO
OMe
N
Boc
a
a. nBuLi, THF, -40 °C; then 9-MeO-9-BBN; b. [(dppf)PdCl2], THF, reflux, 82%; c. PtCl2 (20 
mol %), toluene (0.05 M), 60 °C, 3 h, 97%; d. aq. HCHO, HCl/EtOH, 80 °C, 67%.
b
c d
3 4 5
6 7
MeO
MeO
OMe
N
Scheme 2
8
 
Another common strategy used to construct phenanthrene-type alkaloids is 
that of an intramolecular Friedel-Crafts acylation reaction. The synthesis of (+)-
tylophorine (15) by Rapoport and coworkers serves as a prototypical example of this 
approach (Scheme 3).36     Using a chiral-pool approach, aldehyde 9 was transformed 
into glutamate derivative 10 via a reductive amination reaction.  This intermediate 
was cyclized under acidic conditions and treated with MeOH and KOH to afford 
 22 
pyroglutamate derivative 12. Acid 12 underwent the key Friedel-Crafts acylation 
reaction by converting the acid to the acid chloride and that was followed by 
treatment with SnCl4 afforded the desired lactam 13 in good yield.  Ketone 13 was 
reduced in a two-step fashion by treatment with either Adam’s catalyst or L-
Selectride to give the corresponding alcohol followed by treatment with SOCl2 
followed by hydrogenation that yielded intermediate 14.  A final reduction with LAH 
gave the desired natural product, (+)-tylophorine (15), in excellent yield. 
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a, b
Scheme 3
9
a.  (S)-diisopropylglutamate, CH2Cl2, HOAc, reflux; b.  NaCNBH3, 
isopropanol, HOAc; c.  MeOH/AcOH (2:1), 45 °C, 3 h; d.  KOH, MeOH, 
dioxane, 88% (from 9); e.  (COCl)2, DMF, CH2Cl2, then SnCl4, reflux, 
94%; f.  H2/Pd(OH)2-C, dioxane, 95% (!/" = 4:96) or L-Selectride, THF, 
95%, (!/" = 97:3); g.  SOCl2, CH2Cl2, then H2/10% Pd-C, EtOH, 88% (2 
steps); h.  LAH, THF, reflux, 96%.
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The use of an intramolecular Diels-Alder reaction to assemble the non-
aromatic portion of the molecule is another commonly employed strategy used in the 
syntheses of these natural products. This synthetic strategy was first used by Weinreb 
and coworkers and later by Grieco et al. in their respective syntheses of (±)-
cryptopleurine (8, Scheme 4).37-39 In the Weinreb route, ester 16 is initially 
transformed to aldehyde 17 that then undergoes a Wittig reaction to give acid 18 in 
moderate yield and selectivity.  The acid is transformed to amide 19 and upon 
treatment with paraformaldehyde followed by the addition of acetic anhydride affords 
the desired intramolecular Diels-Alder substrate 20.  Upon heating in 1,2-
dichlorobenzene, amide 20 is first converted to acyl imine 21 in situ that  undergoes 
the key intramolecular Diels-Alder reaction to afford lactam 22.  A subsequent 
reduction with LAH  gives the desired phenanthroquinolizidine alkaloid 8. 
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a, b
Scheme 4
16
a.  LAH, THF, 80%; b.  PCC, CH2Cl2, 98%; c.  Ph3
+(CH2)4CO2HBr
-, TMEDA, 
LDA, THF, 60% (E/Z = ~3:1); d.  ClCO2Et, pyridine, THF, conc. NH4OH, 89%; 
e.  (CHO)x, Ce2CO3, THF, then Ac2O, cat. pyridine, 52%; f.  1,2-Cl2C6H4, 210-
212 °C, 70 min, 66%; g.  LAH, THF, 53%.
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Assembling the indolizidine or quinolizidine nucleus (rings D and E) prior to 
the phenanthrene portion has been utilized. In these cases, ring C is assembled 
through a bi-aryl coupling reaction.  Kibayashi and coworkers implemented this 
strategy through the use of an intramolecular aldol approach in the synthesis of (±)-
tylophorine (31, Scheme 5).40 A regioselective 1,3-dipolar cycloaddition with styrene 
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derivative 23 and pyrroline oxide 24 was used to afford isoxazole 25 as an 
inseparable diastereomeric mixture.  This was inconsequential, as an oxidation later 
in the synthetic route would remove one asymmetric center.  Hydrogenation followed 
by acylation  gave amide 27 in good yield that was subsequently oxidized to yield 
ketone 28.  Intermediate 28 was  subjected to an ethanolic KOH solution to afford the 
desired intramolecular aldol product 29 in excellent yield.  Reduction with LAH 
afforded (±)-septicine (30) and further treatment with I2 under photochemical 
irradiation afforded the natural product (±)-tylophorine (31).  This synthetic strategy 
has also been used for the synthesis of  (±)-cryptopleurine (8).41,42 
 27 
a
Scheme 5
23
a.  toluene, reflux, 3 h, 88% (cis:trans = 5:2); b.  H2, 10% Pd-C, MeOH, rt, 
86%; c.  3,4-dimethoxyphenylacetyl chloride, K2CO3, CH2Cl2, 70%; d.  CrO3, 
CH2Cl2, 86%; e.  5% KOH, EtOH, reflux, 90 min, 95%; f.  LAH/AlCl3 (3:1), 
Et2O/THF, 88%; g.  I2, CH2Cl2, h!, 43%.
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Comins and coworkers have used N-acyldihydropyridone chemistry 
developed in their laboratories for the construction of several members of this class of 
alkaloids.43,44 The synthesis of (-)-tylophorine serves as a model of this synthetic 
strategy (Scheme 6).  First treating pyridinium 32 with but-3-enylmagnesium bromide 
followed by an acidic workup furnishes enaminone 33 in good yield.  Conversion of 
the terminal alkene to the primary alcohol 34 occurs in excellent yield over a two-step 
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protocol.  The alcohol is converted to the corresponding chloride 35 that upon 
treatment with sodium methoxide initially removes the chiral auxiliary and an 
ensuing intramolecular cyclization affords the enaminone 36 in excellent overall 
yield.  Conversion of the triispropyl moiety to the bromide derivative proceeded 
smoothly; this intermediate underwent treatment with L-Selectride and the resultant 
enolate was trapped with 2-(Tf)2N-5-Cl-pyridine, a reagent developed in the Comins 
group,45 to afford the desired triflate 38.  A subsequent double Negishi cross-coupling 
reaction afforded enantiopure (-)-septicine (39) in good yield.  An oxidative bi-aryl 
coupling reaction was then utilized to afford (-)-tylophorine (40). 
a
Scheme 6
32
a.  i.  CH2CH(CH2)2MgBr, THF, ii.  H3O
+, 91%; b.  i.  OsO4, cat. NaIO4, ii.  L-Selectride, 
81%; c.  PPh3, NCS, CH2Cl2, 96%; d.  NaOMe, MeOH, 91%; e.  pyr•HBr3, CH2Cl2, 
LiCO3, 95%; f.  i.  L-Selectride, THF, -78 °C, ii.  2-(Tf)2N-5-Cl-pyridine, 71%; g.  3,4-
(MeO)2C6H3-ZnBr, Pd(PPh3)4, THF, 60 °C, 67%; h.  VOF3, TFA, 68%, >98% ee.
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 The biosynthesis of these alkaloids, namely tylophorine and tylophorinine, has 
been investigated.  Through the use of feeding experiments with labeled precursors 
using Tylophora asthmatica, the biosynthetic pathway for this class of natural 
products has been deduced (Scheme 7).46-52 Initially, phenylalanine is converted to 
cinnamic acid (41) and subsequently into acid 42.  This intermediate  reacts with Δ1-
pyrroline 43, derived from ornithine, to afford phenacylpyrrolidine 46 that reacts with 
aldehyde 45, which originates from either DOPA or tyrosine, to give enamine 47. An 
intramolecular condensation reaction ensues to give indolizidine 48.  After two 
catecholic methylations, bis-methoxy indolizine 49 undergoes an intramolecular bi-
aryl oxidation reaction to afford intermediate 50 that rearranges to cation 51.  This 
transient species is transformed into (+)-tylophorine (15) after an aromatization and 
bis-methylation.  Presumably cryptopleurine is biosynthesized in a similar manner via 
the Δ1-piperidine instead of the Δ1-pyrroline.51 
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Although the phenanthrene-type alkaloids have been known for some time, 
only tylocrebrine, due to its antileukemia activity,53 has advanced into clinical trials 
but was discontinued due to neurological toxicity.54 The Georg group has 
hypothesized that this toxicity may be due to tylocrebrine’s similarity to dopamine 
(Figure 2A). The natural product may be acting like a dopamine mimic in the CNS 
and thus causing the observed unwanted side-effects.  Also, these natural products are 
known to readily undergo oxidation to the pyridinium species in the laboratory and 
this could occur presumably by monoamine oxidase B in vivo.  Therefore the 
untoward effects may be related to the Parkinson-like symptoms analogous to those 
caused by MPP+ (Figure 2B).55 However, the actual mechanism(s) for the 
neurological side-effects caused by the natural product still remain unclear. 
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Figure 2.  Hypothesized CNS neurological toxicity mechanisms of tylocrebrine.
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In recent years, these alkaloids and their analogues have reemerged as 
potential anticancer agents in part due to the recent advances in chemical and 
molecular biology.  In particular, simplified and hydrophilic analogues of the parent 
phenanthroindolizidines and phenanthroquinolizidines have been prepared in order to 
overcome the unwanted neurological side effects seen with tylocrebrine.20,21  These 
analogues, although generally not as potent as the parent molecules, have retained 
cytotoxic activity, but interestingly, some analogues demonstrate a differing 
mechanism-of-action compared to the parent compound or even analogues within the 
same series of compounds.7 In addition, no general structure-activity relationship 
(SAR) has emerged from these analogues and the SAR of each series appears to be 
target and/or tissue specific.   
1.2 Retrosynthesis 
In an antithetic sense, boehmeriasin A (1) was to be synthesized using the 
general N-acyldihydropyridone strategy discussed above (Scheme 8). Only the 
racemic natural product is shown for clarity; however, the same synthetic strategy for 
both the racemic and enantiopure syntheses was to be used.  The natural product was 
envisioned to be derived from an intramolecular bi-aryl coupling of the seco-natural 
product which itself was to be accessed from a palladium-mediated cross-coupling 
reaction.  The triflate coupling partner for the cross-coupling was to be obtained using 
a literature procedure for the conversion of cyclic enaminones to triflates in a one-pot 
synthetic operation that was to occur on arylated enaminone 53.  This advanced 
intermediate was envisioned to arise from a novel, palladium(II)-catalyzed  
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C-H functionalization utilizing organotrifluoroborates.  The enaminone coupling 
partner for this transformation would be attained from Weinreb amide 55 through 
methods developed in the Georg laboratories. 
1.3 Synthesis of α-Arylated Enaminones 
Weinreb amides 55, 58, and 59 were prepared from either known ester 5635 or 
the corresponding commercially available (S)- or (R)-acids 57, respectively (Scheme 
9).56 Each of the amides was treated with ethynylmagnesium bromide to afford the 
corresponding ynones 60-62 in excellent yields (Scheme 10).57   These compounds 
were subjected to a one-pot, two-step protocol for the cyclization of Boc-ynones to 
enaminones using conditions developed in the Georg laboratories.56,58 In this 
protocol, the ynone is treated with formic acid and NaI to give the corresponding 
vinyl iodide that is subjected to a methanolic K2CO3 solution to afford the 
enaminones 54, 63 and 64 in excellent yields.58 This modification of the reported 
procedure was developed to minimize racemization that was found to occur in the 
original report (Scheme 11). Mechanistically, treatment of the ynone with formic acid 
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and NaI adds an equivalent of HI across the ynone to generate the vinyl iodide 
species 68 and eventually intermediate 69 is formed after Boc removal.  Upon 
treatment with a methanolic K2CO3 solution, the protonated amine is first 
deprotonated, which attacks the vinyl iodide to give transient species 71 in a 6-endo-
trig manner.  A subsequent elimination of the iodide affords the desired enaminone 
54. 
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Scheme 10
a.  ethynylmagnesium bromide, THF, -78 °C to rt; (±)-60, 93%; (S)-61, 90%; (R)-62, 
91%; b. formic acid, NaI; then K2CO3, MeOH; (±)-54, 94%; (S)-63, 87%; (R)-64, 91%; 
c. potassium 3,4-dimethoxyphenyltrifluoroborate (65), Pd(OAc)2, Cu(OAc)2, K2CO3, 
tBuOH/AcOH/DMSO (20:5:1), acetone/H2O (2:1); (±)-53, 84%; (S)-66, 77%; (R)-67, 
76%.
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With rapid access to the desired enaminones established, a novel 
palladium(II)-catalyzed C-H functionalization using enaminones and potassium 
organotrifluoroborates was employed.59 The proposed mechanism for this 
transformation is depicted in Scheme 12.  Palladation of the enaminone 54 occurs 
first via electrophilic attack of Pd(OAc)2 on the enaminone followed by deprotonation 
to yield intermediate 72.  Transmetallation ensues and a subsequent reductive 
elimination occurs to give the desired coupled product 74.  However, an alternative 
mechanism may also be operational.  Transmetalation may occur prior to palladation 
of the enaminone giving rise to homocoupled products that are observed  
reaction products.59 This method represents a powerful means of accessing these 
products, as previous methods required an initial prefunctionalization of the 
enaminone to the appropriate α-halogenated derivative followed by Suzuki 
coupling.60 This protocol obviates this requirement and thus allows for a more facile 
means of accessing these compounds.  Gratifyingly, using a slight modification of the 
reported procedure for scale-up purposes employing the coupling partner potassium 
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3,4-dimethoxyphenyltrifluoroborate (65), prepared according to a known procedure,61 
afforded good yields of the desired coupled products 53, 66, 67 (Scheme 10). 
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1.4 Completion of Synthesis 
With a route to the envisioned α-arylated products now in place, the final 
synthetic sequence was undertaken (Scheme 13).  Utilizing a procedure developed by 
Comins and coworkers, enaminones 53, 66, and 67 were treated with L-Selectride 
and the resultant enolates were trapped with Comins’ reagent to arrive at the desired 
triflates 75-77 in good yields.43 The intermediates were initially subjected to a Suzuki 
coupling using commercially available potassium 4-methoxyphenyltrifluoroborate 
with conditions developed by Buchwald et al.62 However, during the course of this 
reaction a side-product was generated that was difficult to remove completely from 
the product by all chromatographic means attempted. Additionally, in some reaction 
attempts variable amounts of the reduced product 78 were produced.  To overcome 
this problem, a Negishi cross-coupling reaction was implemented which furnished 
easily purified products and near quantitative yields of the desired seco-natural 
products.43   
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a.  L-Selectride, THF, -78 °C to rt, then Comins' reagent; (±)-75, 85%; (S)-
76, 77%; (R)-77, 68%; b.  79, Pd(PPh3), THF, 60 °C, 1 h; (±)-80, 97%; (S)-
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 The synthesis was completed with a VOF3-mediated bi-aryl ring closure to 
afford (±)-boehmeriasin A (1), (S)-boehmeriasin A (83), and (R)- boehmeriasin A 
(84) in good yields.37   These conditions proved optimal because the use of other 
oxidants (e.g. PIFA63 or FeCl364) resulted in a difficult to remove side-product, which 
is believed to be the regioisomeric product.  The formation of this side product is 
completely suppressed through the use of VOF3 in acidic media at low temperature.  
The final products were crystallized from CH2Cl2/MeOH and the crystal structure for 
the (R)-antipode is shown in Figure 3. The spectral data of the synthetic natural 
product was consistent with those reported for the isolated natural product.  In 
addition, the specific rotation of the (R)-enantiomer gave a matching sign and 
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magnitude with those found in the literature (lit. -80, MeOH, c = 0.10; obs. -86, 
MeOH, c = 0.10)13 and thus establishing the absolute stereochemistry of the natural 
product. 
 
Figure 3.  Crystal structure of (-)-(R)-boehmeriasin A. 
1.5 Biological Evaluation 
 The natural products and synthetic intermediates were subjected to 
cytotoxicity assays to confirm the reported biological activity and establish an initial 
SAR for boehmeriasin A in breast (MCF7), ovarian drug-resistant (NCI-ADR-RES), 
and colon (COLO-205) cancer cell lines (Table 1).  Enaminone 54 and arylated 
enaminone 53 did not display any cytotoxic activity in any of these cell lines.  
Compound 78 and seco-boehmeriasin A 80 were also void of any cytotoxic activity in 
the cell lines evaluated.  However, racemic boehmeriasin A (1) did show potent 
cytotoxic activity.  This indicates that a full phenanthrene ring system is required for 
potent cytotoxic activity.  This is in accord with other studies of synthetic analogues 
of this class of natural products.20 (-)-Boehmeriasin A (84) was much more potent 
than its antipode, (+)-83, in all of the cell lines evaluated.  Important to note is that all 
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of the natural product derivatives showed activity in the drug resistant cancer cells, 
NCI-ADR-RES, where paclitaxel is inactive.  Additionally, the hydrochloride salt of 
(±)-boehmeriasin A also demonstrates potent cytotoxic activity in these cell lines.  
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1.6 Conclusions 
In conclusion, the first total synthesis of (-)-(R)-boehmeriasin A was 
accomplished in seven steps from commercially available material with an overall 
yield of 29% and the absolute stereochemistry of the natural product was determined 
to be of the (R)-configuration.  The synthetic route deserves several comments. 
Boehmeriasin A is the first phenanthroquinolizidine alkaloid to be prepared using 
novel enaminone chemistry developed in the Georg group laboratories.  In addition, 
this research for the first time utilizes a palladium(II)-mediated C-H functionalization 
of a quinolizinone in a total synthesis. When evaluated for cytotoxic activity, (-)-(R)- 
boehmeriasin A demonstrates potent cytotoxicity in several different cancer cell lines.  
From the analogues evaluated, some initial SAR could be deduced.  First, a full 
phenanthrene is required for cytotoxic activity because synthetic intermediates 
lacking any portion of this ring system were void of anticancer activity.  Also, it was 
found that the (R)-enantiomer is more potent compared to its antipode in all cell lines 
evaluated and the hydrochloride salt of (±)-boehmeriasin A also demonstrates potent 
cytotoxic activity.  In addition, these compounds display potent cytotoxic activity in 
drug resistant cancer cells where paclitaxel is inactive.  
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Chapter 2 
Development of a Sequential, One-Pot Synthesis of Chromones 
 
2.1 Background 
The chromone motif and its derivatives are privileged structures that 
demonstrate a wide range of biological activities (Figure 4).65 These secondary 
metabolites are produced by polyketide synthases encoded in the chromosomes of a 
variety of organisms, typically of plant origin.66,67 The isolated natural products 
frequently consist of highly oxygenated chromones that act as free radical scavengers 
or as defenses against external stressors for the producing organism.67 Of the wide 
array of biological activity displayed by chromones, they are known primarily for 
their antioxidant activity.68-70 Additional pharmacological activities displayed by 
these compounds include antiinflammatory, antitumor, and antimutagenic 
properties.71,72 It has been postulated that their impressive biological activity results 
from the ability of chromones to act as ATP mimics in various biological targets.73 
Due to their broad biological profiles, these natural products have often been used as 
lead compounds in medicinal chemistry programs. Several chromone compounds, 
namely flavones, have been recently introduced into clinical trials for the treatment of 
ulcerative colitis and angiogenesis inhibition.2 As a continuation of the Georg group’s 
interest in chromones as biological probes,74 efforts towards a general method for the 
construction of chromones via a sequential, one-pot synthetic route are presented. 
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2.2 Previous Routes to Chromones 
The most popular method for the construction of chromones is the Baker-
Venkataraman rearrangement (Scheme 14).75,76 In this reaction substituted 2-hydroxy 
acetophenones 86 are converted to esters 87, which rearrange under basic conditions 
to afford diketones 88.  These intermediates cyclize to chromones 89 under rather 
harsh conditions, for example, by treatment with concentrated sulfuric acid or heating 
with glacial acetic acid. However, variants that use milder reagents have been 
developed.77 Another common method to access these compounds involves the 
intramolecular Michael addition of 2-hydroxyphenyl ynones 90 into the 
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corresponding 1,4-benzopyrones 89 (Scheme 14).78 This strategy generally affords 
good yields of the desired chromone. Until recently, however, synthesis of the 
cyclization precursors (i.e. ynones) have relied upon toxic reagents (e.g. HgCl2, PDC, 
or 18-crown-6) and/or suffered from poor yields.79-82 In addition, the one-step 
synthesis of chromones has been reported but mixtures of flavones and aurones were 
produced in modest yields.83 A similar approach was used for the synthesis of 
flavones and quinolones that required the use of high temperatures and resulted in 
modest to good yields of the desired products.84 
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2.3 Diversity-Oriented Synthesis Approach to Chromones 
Ideally a mild and highly efficient synthesis of the chromone core, which does 
not require the use of large quantities of toxic chromium or mercury reagents, could 
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be employed to construct a variety of these compounds for use in diversity-oriented 
synthesis (DOS).85-87 The underlying tenet of DOS is to efficiently prepare collections 
of skeletally diverse small molecules intended to mimic natural product scaffolds. 
Natural product-like compounds are desired as foundations for lead entities as these 
entities have been selected over time to contain motifs (i.e. privileged structures) that 
elicit biological activity.88 Accordingly, the privileged nature of the chromone motif 
makes it an excellent starting point for the generation of DOS-based libraries.  Not 
surprisingly, libraries based on the chromone scaffold have been reported.89-98 In 
addition, these scaffolds have inspired the development of new polymer-bound 
reagents for use in their construction.99-101 Although these methods afforded libraries 
of chromone derivatives, they were limited in substrate scope.  Therefore, a more 
general method allowing access to a diverse set of chromones for use in DOS was 
desired.  A library of unique chromones, located in relatively unpopulated chemical 
space, would add value to any high-throughput screening set due to their privileged 
nature.  
A hypothetical library of unique chromones was envisioned upon 
development of a new route to these compounds (Scheme 15). Chromone 91 would 
first be treated with isocyanates and the resulting ureas  would undergo an amidation 
reaction to afford a library of chromones 92.  These intermediates can be further 
transformed into subsequent libraries of pyrazoles 93, pyrimidines 94, or amino 
pyrimidines 95 via treatment with hydrazines, amidines, or guanidines, respectively, 
via reaction of the latent 1,3-dicarbonyl.94,95 
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2.4 Chromone Synthesis via Gold Catalysis 
Gold catalysts are well known for their unique ability to coordinate to alkynes.  
This coordination renders the alkyne electrophilic and prone to nucleophilic attack or 
rearrangement to afford unique skeletons.102,103 These catalysts assist in the efficient 
construction of diverse molecular structures, in particular carbocycles and 
heterocycles, with great synthetic efficiency that would be difficult to prepare by 
other methods. As ynones are useful synthons56 and no previous reports utilizing gold 
catalysis with these substrates were known, the feasibility of preparing chromone 
derivatives via intramolecular cyclization using gold catalysis was undertaken. The 
reaction pathway envisioned for this process is depicted in Scheme 16.  Initial 
coordination of the catalyst to the ynone 96 gives complex 97 that can be cyclized in 
either a 6-endo-dig or 5-exo-dig fashion.  Attack at the β-position produces 
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intermediate 98 followed by a proton transfer giving chromone 99.  However, 
nucleophilic attack at the α-position yields gold complex 100 that is subsequently 
converted into aurone 101.  In order to test the viability of this reaction pathway, an 
efficient synthetic route to the requisite phenolic ynones was developed.  
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2.5 Synthesis of Phenolic Ynones 
As an initial model system to test these synthons as cyclization substrates, 
ynone 107 was synthesized in a sequential, one-pot fashion through a modification of 
a literature procedure (Scheme 17).97 Protection of aldehyde 102 with MOM-Cl, 
followed by treatment with lithiated phenyl acetylene, oxidation with MnO2, and 
deprotection with TFA gave ynone 107 in good overall yield and required only a 
single chromatographic purification at the end of the synthesis. This route was chosen 
over previous methods as this would allow synthetic intermediates at be utilized for 
subsequent DOS-based libraries.  With an efficient route to the cyclization substrate 
in place, investigation into the gold-mediated cyclization was explored. 
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a. MOM-Cl, DIEA, CH2Cl2; b. nBuLi, HCCPh (103), THF then aldehyde, 0 ºC 
to rt; c. MnO2, 1,2-dichloroethane, reflux; d. TFA, CH2Cl2; 74% (4 steps).  
2.6 Optimization of Ynone Cyclization  
Screening several commercially available gold catalysts in acetonitrile and 
several temperatures resulted in very slow reactions producing only trace quantities of 
flavone (108) (Table 2, Entries 1-4).  Presumably this is a consequence of the 
electron-deficient nature of the ynone reducing its ability to coordinate to the catalyst.  
In an attempt to increase the reaction rates, K2CO3 was added to increase the 
nucleophilicity of the phenolic moiety for attack of the ynone (Entry 5).  Complete 
consumption of starting material was observed at room temperature resulting in a 
mixture of the corresponding flavone and aurone (85:15).  However, carrying out the 
reaction without the gold catalyst resulted in only the flavone being isolated (Entry 6).  
Thus, a gold catalyst was not required for the cyclization to occur which is in 
agreement with previous reports.79-81 However, these examples utilized refluxing in 
either MeOH or acetone whereas stirring in acetonitrile at room temperature is 
sufficient for cyclization to occur.  An analogous cyclization was recently reported 
utilizing AuCl and propargyl alcohols followed by an oxidation to access the 
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corresponding aurones.104 This report corroborated our results that prolonged reaction 
times produce low yields of flavones when utilizing only the gold catalyst in 
conjunction with ynones. In addition, treating ynones similar to compound 107 with 
other transition metals (e.g. Pd or Ag) also results in aurone formation.105,106 
Deprotection with 4 M HCl in dioxane and cyclization and K2CO3 in MeOH which 
were previously used to construct enaminones from Boc-ynones were also 
examined.56 These conditions resulted in the formation of an undetermined side-
product. Therefore, deprotection with TFA and cyclization with K2CO3 in acetonitrile 
at ambient temperature were deemed to be the optimal conditions to access the 
chromones.   
Conditions
OH
O
Ph
O
O
Ph O
O
Ph
+
Table 2.  Optimization of cyclization conditions.
108 109107  
Entry Catalyst Solvent Base Temp 
(ºC) 
Time 
(h) 
Flavone Aurone 
1 AuCl3 MeCN none 80 12 Trace -- 
2 AuCl MeCN none 80 12 no 
reaction 
-- 
3 (PPh3)AuCl wet 
MeCN 
none rt 12 Trace -- 
4 AuCl3 wet 
MeCN 
none rt 12 no 
reaction 
-- 
5 AuCl3 wet 
MeCN 
K2CO3 rt 2 85 15 
6 none wet 
MeCN 
K2CO3 rt 4 >95% -- 
 
2.7 Development of a Sequential, One-Pot Synthesis of Chromones 
An investigation to determine if the above synthetic steps would be amenable 
to a sequential, one-pot endeavor starting with aldehyde 102 was next evaluated 
 51 
(Scheme 18). An analogous route has been reported but resulted in a moderate overall 
yield utilizing large excesses of toxic chromium and mercury reagents.77 
Additionally, purifications were performed after each reaction in the sequence.  When 
salicylaldehyde (102) was subjected to the optimized procedure, flavone (108) was 
obtained in excellent yield over the five-step sequence. A single chromatographic step 
at the end of the series proved to be an acceptable means to access chromone 108. 
Thus, conditions for a high-yielding, operationally mild, one-pot protocol for the 
synthesis of chromones were established. 
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Scheme 18
108
a. MOM-Cl, DIEA, CH2Cl2; b. nBuLi, HCCPh (103), THF 
then aldehyde, 0 ºC to rt; c. MnO2, 1,2-dichloroethane, 
reflux; d. TFA, CH2Cl2; e. K2CO3, MeCN, 77 %, (5 Steps).
102
 
2.8 Exploration of Scope of Optimized Route 
With the optimized five-step sequence in place, a series of flavone derivatives 
was prepared to explore the scope of the reaction sequence (Table 3). The electronic 
nature of the ynone was evaluated and all variants (e.g. electron-neutral, electron-rich, 
and electron-poor ynones) underwent cyclization resulting in synthetically useful 
yields of the corresponding flavones (Entries 1-3).  Altering the electronic nature of 
the aromatic rings does slightly lower the overall isolated yield.  Previous reports 
suggest that the reaction occurs through a vinylic carbanion.78  Therefore modifying 
the electronic nature of the ynone substituent renders a less stable carbanion at the α-
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position, resulting in lower chromone product formation. Small amounts of the 
corresponding aurone were detected in these cases.  The aurones and chromones can 
be easily distinguished from one another through several different methods.  
Chromatographically, the aurones are generally less polar on TLC (silica gel) 
compared to flavones.  In addition, the vinyl proton of aurones is commonly shifted 
more downfield (i.e. >6.8 ppm) when compared to the analogous proton in flavone 
systems (i.e. <6.8 ppm).  Sterically demanding aryl moieties also provide good yields 
of the corresponding chromones; however, significant amounts of the corresponding 
aurones are also produced (Entry 4).  This suggests that steric hindrance in proximity 
to the ynone plays a greater role in the regioselective outcome than the electronic 
character of the ynone using this protocol. Heteroaromatic rings are also suitable 
reaction substrates (Entry 5). TMS-protected and alkyl ynones furnished the desired 
chromone in excellent overall yields (Entries 6 and 7).  The low isolated yields of the 
chromones 122, 123, and 125 were unexpected (Entries 8 and 9).  The lower yields 
observed in these cases are hypothesized to result from an intermolecular attack of the 
free alcohol once the chromone has been generated.  Accordingly, protection of the 
free hydroxyl moiety as a methyl ether results in a significantly increased overall 
yield compared to the free hydroxyl case (Entry 10).  The electronic character of the 
aldehyde partner was also evaluated and both electron-poor and electron-rich 
functional groups afford good yields of the desired products (Entries 11 and 12). 
Preparation of a natural product-like compound (e.g. rotenone) was also explored and 
gratifyingly the synthetic route was able to afford moderate yields for this example 
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(Entry 13). Notable features of this synthetic route are that only a single purification 
step is necessary and the reaction sequence can tolerate a wide range of functionality, 
which is ideal for library synthesis. 
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Table 3.  Scope of the sequential, one-pot chromone synthesis.
Entry Aldehyde Alkyne Flavone Yield (%)
1 77
2 102 59a
3 102 56b
4 102 72c
5 102 74
6 102 58
7 102 91
8 102
122, R = H; 14%      
123, R = TBS; 13%
9 121 7
10 102 38
11 103 65
12 103 50
13 37
a.  Trace aurone, b.  5% aurone, c.  28% aurone
OH
CHO
102
103 O
O
108
OMe
109
O
O
OMe110
CF3
111
112
O
O
CF3
113
Me
O
O
Me
114
115
S
O
O
S
116
117
TMS
O
O
118
119
C5H11
O
O
120
121
OTBS
O
O
OR
OH
CHO
124
MeO
O
O
OH
MeO
125
126
OMe
O
O
OMe
127
OH
CHO
128
Br
O
O
Br
129
OH
CHO
130
MeO
O
O
MeO
131
OH
CHO
O
132 133
O OMe
OMe
O
O
O
O
OMe
OMe
134
 55 
2.9 Extension to Natural Product Synthesis 
To further extend the scope of this method, the synthesis of the natural 
product, hydroxy-2-(2-phenylethyl)chromone (142), was undertaken (Scheme 19).  
This compound was isolated from the methanolic extract of the rhizomes of Imperata 
cylindrica Beauv. (Gramine) through a bioactivity-guided fractionation screen for 
neuroprotective compounds.107 Chromone 142 was found to significantly protect 
primary cultures of rat cortical cells from glutamate-induced neurotoxicity at 10 µM. 
The synthesis commenced by treating aldehyde 135 with MOM-Cl, lithiated alkyne 
136, and MnO2 to afford the corresponding ynone 139.  This intermediate was 
deprotected and cyclized to afford the penultimate product 141 in 15% overall yield 
from aldehyde 135.  The synthesis was completed by treating chromone 141 with 
BBr3 to afford the natural product 142 in good yield.  The spectral data of the 
synthetic material were consistent with those reported in the literature for the isolated 
natural product.107 
 56 
O
OOH
Ph
a. MOM-Cl, DIEA, CH2Cl2; b. nBuLi, 136, THF then aldehyde, 0 ºC to rt; c. MnO2, 
1,2-dichloroethane, reflux; d. TFA, CH2Cl2; e. K2CO3, MeCN, 15% (5 steps); f. BBr3, 
CH2Cl2; 66%.
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2.10 Conclusions 
A five-step, one-pot procedure for the synthesis of chromone derivatives has 
been developed.  This protocol displays high functional group compatibility, mild 
reaction conditions, high yields, and requires a single chromatographic step after the 
completion of the synthesis.  In addition, this method generally affords excellent 
selectivity of the desired chromone over the aurone products.  During this 
investigation a high-yielding synthesis of ynones, which are excellent substrates for 
constructing DOS libraries, has also been developed.  The above protocol was applied 
to the first total synthesis of 5-hydroxy-2-(2-phenylethyl)chromone (142), a 
neuroprotective chromone isolated from Imperata cylindrica. 
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Chapter 3 
A Preparative Scale Procedure for the Reduction of Tertiary Amides with 
Cp2Zr(H)Cl 
 
3.1 Background 
Amides are prevalent structural units throughout Nature and are inert to many 
chemical transformations.108 However, synthetic methods do exist to convert this 
moiety into the corresponding alcohols, aldehydes, and amines. Many of these 
methods are rather harsh and can affect other functional groups within the same 
molecule, although milder methods have been developed.109 In particular, the 
reduction of amides into the corresponding aldehydes has proven to be a difficult 
synthetic challenge.  Most examples have demonstrated high substrate specificity and 
are commonly affected by the substituents on the nitrogen atom.110,111 In addition, 
conditions used to perform this transformation usually require highly activated 
aluminum or boron reagents that commonly result in over reduction products and low 
levels of chemoselectivity en route to the desired aldehydes. 
Schwartz’s reagent (Cp2Zr(H)Cl), first reported by Wailes and Weigold, is a 
16-electron, d0 complex with the zirconium at an oxidation state of (+4).112,113 The 
remaining valence for the metal renders the molecule Lewis acidic while the absence 
of a valence-shell filled nonbonding orbital leaves the reagent with low nucleophilic 
aptitude.  This empty orbital allows for complexation of the metal to an array of 
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functional groups with nonbonding electron pairs, e.g. π-bonds/electrons and in some 
cases σ-bonds/electrons.114 
The most commonly used synthetic application for this reagent is that of 
hydrozirconation due to its predictable ability to add stereo- and regioselectively 
across π-bonds.115,116 These reactive intermediates can  react with a range of 
electrophiles or undergo carbonylation or halogenation.  Alternatively, the vinyl 
zirconium species can undergo transmetallation to participate in various cross-
coupling reactions.  Additionally, heteroaromatic moieties can be reduced via 
hydrozirconation.117-121 
The Georg group recently reported a general method to convert amides into 
aldehydes using Schwartz’s reagent with excellent chemoselectivity.122-124 
Mechanistically, the reduction of amides with Cp2Zr(H)Cl proceeds through an 18-
electron zirconacycle intermediate that is subsequently hydrolyzed to afford the 
corresponding aldehydes (Scheme 20).  This method is generally tolerant of many 
functional groups, high yielding, and operational under mild reaction conditions in 
very short reaction times. This procedure is able to reduce aromatic, heteroaromatic, 
and aliphatic amides in excellent yields.  Furthermore, this protocol has been 
extended to afford deuterated aldehydes in excellent yields which are useful 
substrates to study enzymatic reactions.122 In addition, primary, secondary, and 
Weinreb amides can all be reduced to the corresponding aldehyde in good to 
excellent yields.  This method has also been applied to the removal of amide-based 
chiral auxiliaries although the resulting yields of the produced aldehydes were 
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substrate specific.  Although amides containing an alkene or alkyne moiety can be 
reduced with this procedure, the corresponding yields are generally reduced 
compared to the previously mentioned examples.  This presumably is a consequence 
of side-reactions with the unsaturated bonds present within these substrates. An 
investigation of sterically hindered amides revealed that this procedure is somewhat 
sensitive to congestion around the amide unit and the corresponding yield is substrate 
specific.  However, Rawal and coworkers developed conditions to circumvent this 
limitation using three equivalents of Cp2Zr(H)Cl in CH2Cl2.125 Although a very 
thorough investigation of the scope and mechanism has been reported on a laboratory 
scale, previously no examination of this procedure on a preparative scale (i.e. >1 g 
scale) has been conducted.  Herein development of a preparatory scale reduction of 
tertiary amides is presented. 
R1 N
O
R2
R3
R1 N
O
R2
R3
ZrCp2Cl
R1
O
H
Silica
Gel
-Cp2ZrClO
-H2NR2R3
H
Scheme 20
143 144 145  
3.2 Preparatory Scale Reduction of Tertiary Amides with Cp2Zr(H)Cl 
Amide 146, prepared from the corresponding acid chloride, was chosen as a 
model substrate to test the feasibility of a preparatory procedure for the reduction of 
tertiary amides to the corresponding aldehyde using the Schwartz reagent (Scheme 
21). In this protocol the readily available Cp2Zr(H)Cl is suspended in anhydrous THF 
under a nitrogen atmosphere and amide 146 in THF is then added to the suspension 
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(Scheme 21).  The reaction is complete within minutes in very good isolated yield on 
multigram quantities. Although this procedure generally afforded good yields of the 
corresponding aldehyde 147, two problems were encountered that needed to be 
addressed upon scale up, which included (1) side-product formation after quenching 
the reaction with silica gel and (2) overcoming the quality of different lots of 
Cp2Zr(H)Cl from commercial vendors. 
NEt2
O
Scheme 21
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MeO
MeO
OMe
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MeO
MeO
OMe
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147
a.  Cp2Zr(H)Cl, THF; 99%.  
The first issue to be addressed when conducting the reactions was a 
problematic side reaction that resulted in intractable reaction mixtures. In some 
reactions a bright yellow/orange by-product was observed that was not noticed on 
smaller scale reaction (i.e. <100 mg) and was difficult to separate from the aldehyde.  
This impurity was not observed during the course of the reaction but only appeared 
after quenching the reaction with silica gel. Identifying the isolated impurity was 
unsuccessful; however, its presence seemed temperature and concentration dependent 
in the presence of silica gel.  Generally by-product formation was noticed during 
evaporation of the solvent from the crude reaction mixture and increased amounts 
were observed when heating the flask containing the crude reaction/silica gel mixture 
above 30 ºC during this time.  The resulting impurity was observed as a change in 
color of the silica gel from a pale yellow to orange-red.  In addition, exposing the 
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crude aldehyde to silica gel for more than 30 minutes under high-vacuum conditions 
also led to increased amount of this by-product.  Not surprisingly, increased amounts 
of the impurity led to a decreased amount of the isolated aldehyde and difficult to 
purify reaction mixtures. Varying the amount of silica gel or alternatively using celite 
or neutral alumina as a replacement for the silica gel were attempted but side-product 
formation was also observed in these cases.  It was hypothesized that prolonged 
exposure to the solid medium needed to be minimized but long enough to sequester 
the zirconium by-products in order to obtain the desired aldehyde without side-
product contamination.  As such, upon complete consumption of amide, silica gel was 
added to the reaction and stirred for five minutes under ambient conditions.  The 
heterogeneous mixture was filtered and washed with diethyl ether.  The filtrate was 
concentrated and purified under standard chromatographic conditions.  This did 
greatly reduce the observed by-product formation.  However, some zirconium oxide 
by-products were not always completely sequestered and leached through into the 
filtrate and occasionally resulted in observable by-product formation.  Thus, an 
additional workup step was implemented.  After filtration, the filtrate was  subjected 
to an aqueous workup to remove any remaining zirconium by-products from the 
crude mixture.  This procedure was effective in providing the desired reaction product 
without observable by-product formation.  Important to note is that the order of steps 
is crucial because conducting an aqueous workup of the reaction mixture (i.e. without 
a silica gel quench) results in difficult to break emulsions.    
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A second matter to address when conducting these reactions on a preparatory 
scale was the quality of the Schwartz reagent itself. The yields of the isolated 
aldehyde were highly dependent on the source and lot of the reagent used. Although 
this reagent can be prepared from Cp2ZrCl2,126 most commonly this reagent was 
purchased from commercial vendors, due to ease of access and availability, and 
generally successful reactions were observed. However, inconsistencies in the quality 
of the commercial reagent were observed here and also recently in a procedure for the 
directed hydrozirconation of homopropargylic alcohols.127 Early experiments required 
only 1.2 equivalents of Cp2Zr(H)Cl for the reaction to go to completion.  However, in 
subsequent experiments, using a different lot of the commercial reagent, more 
Cp2Zr(H)Cl was needed for complete consumption of the starting amide.  The use of 
2 equivalents was enough to overcome this discrepancy in quality from lot-to-lot and 
afforded complete reactions in very short reaction times. Thus, the best conditions for 
preparatory reductions of amides with Cp2Zr(H)Cl involve the use of 2 equivalents of 
the Schwartz reagent and upon complete consumption of starting material, quenching 
the reaction with silica gel, filtering, and subjecting the filtrate to an aqueous workup.  
Important to note is that the amount of Schwartz’s reagent used when reducing 
tertiary amides might be amenable to less than 2 equivalents depending on the 
particular substrate of interest to provide a more economical reaction.  
3.3 Scope of Reduction of Amides with Schwartz’s Reagent 
With an optimized preparatory procedure now in place, this procedure was 
tested on a representative set of tertiary amides to examine functional group 
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compatibility on a preparatory scale (Table 4). Both neutral and electron-deficient 
aromatic amides are readily reduced affording the corresponding aldehydes in good 
yields (Entries 1 and 2).  Demonstrated in Entry 3, selective amide reduction occurs in 
the presence of an ester in good yield.  In addition, bulky amides and non-aromatic 
amides can be reduced to the corresponding aldehydes in excellent yields (Entries 4 
and 5).   
NEt2
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Entry Amide Aldehyde Time (min)
1
O
NEt2
Cl
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O
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3
O
NEt2
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O
O
Cl
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O
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H
H
H
H
Yield (%)
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92
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Scale 
(mmol)
20
11
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715
MeO2C MeO2C
Table 4.  Scope of Optimized Prepatory Scale Procedure.
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3.4 Conclusions 
In conclusion, a mild and operationally simple method for the selective 
reduction of tertiary amides to aldehydes using Cp2Zr(H)Cl on a preparatory scale is 
presented, employing a modified workup procedure.  It is well known that conditions 
used on a laboratory scale sometimes need revision on preparatory scale and that was 
found here.  Through a modified workup procedure, by-product formation that was 
not previously observed on a laboratory scale was suppressed.  This method offers an 
alternative to known methods that are either substrate selective or can result in over-
reduction products. In addition, this reaction can be conducted in the presence of 
esters and results in selective reduction of the amide to afford the corresponding 
aldehyde.  Therefore, this procedure is a significant improvement over known amide 
reduction methods due to its mild and selective nature. 
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Chapter 4 
Experimental 
4.1 Materials and Methods 
Melting points were determined using a melting point apparatus and are 
uncorrected.  Infrared spectra were obtained as thin films on NaCl plates using an FT-
IR instrument.  NMR experiments were performed on a 400 MHz instrument using 
the residual solvent peak as internal standard unless otherwise indicated. Samples 
obtained in CDCl3 were referenced to 7.26 ppm for 1H and 77.16 for 13C and samples 
obtained in d6-DMSO were referenced to 2.50 for 1H and 39.52 for 13C.128 All 
chemical shifts were recorded in parts per million (ppm) and coupling constants (J) 
are in Hz and assigned according to the procedure of Hoye and coworkers.129 The 
multiplicities of the signals are described using the following abbreviations: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad.  Specific 
rotations were obtained using a polarimeter at 25.0 ºC.  High-resolution mass spectra 
were obtained utilizing the electrospray ionization technique. 
All reactions were performed under an atmosphere of nitrogen in flame-dried 
glassware unless otherwise indicated. THF, CH2Cl2, and DMF were dried and 
deoxygenated by passing the nitrogen-purged solvents through activated alumina 
columns on a solvent purification system.  All other reagents and solvents were used 
as purchased.  Reaction progress was monitored by thin layer chromatography (TLC, 
silica gel, 10 × 20 cm, 250 micron) visualizing with UV light (254 nm) or developing 
the plates with either ninhydrin or phosphomolybdic acid/Ce(SO4)2 stains.  All 
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compounds were purified using either MPLC, using either silica gel (60 Å, 230-400 
mesh), neutral alumina (58 Å, ~150 mesh), or standard flash chromatography 
techniques utilizing the indicated conditions.  All compounds were concentrated 
using standard rotary evaporator and high-vacuum techniques.  HPLC analysis was 
conducted on an HPLC system equipped with a photodiode array detector.  UPLC-
MS analysis was used to determine product purities. All compounds were purified to 
>95% homogeneity prior to biological evaluation.  
4.2 Experimental Procedures 
4.2.1 Chapter 1 
N
Boc
O
EtO
 
tert-Butyl-2-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate (56). Ethyl 2-(pyridin-
2-yl)acetate (16.5 g, 100 mmol) and Boc2O (48.10 g, 220 mmol) in ethanol (1 L) was 
placed in a flow hydrogenator equipped with a 10% Pd-C cartridge.  The reaction was 
allowed to react at 0.5 mL/min at 70 °C with 30 bar H2 pressure in a closed-loop 
fashion until TLC analysis (50% ethyl acetate in hexanes) indicated complete 
consumption of starting material (~7 d).  The resulting clear solution was 
concentrated and purified my MPLC (0-50% acetone in hexanes, 210 nm, 50 min) to 
give 25.49 g of a pale yellow oil (89%).  The spectral data are consistent with those 
reported in the literature.35  1H NMR (400 MHz, CDCl3) δ 1.25 (3H, t, J = 7.1 Hz), 
1.45 (9H, s), 1.49-1.70 (6H, m), 2.52 (1H, dd, J = 4.6, 10.7 Hz), 2.49-2.59 (1H, m), 
2.77 (1H, t, J = 12.7 Hz), 3.98 (1H, d, J = 12.2 Hz), 4.11 (2H, q, J = 2.1 Hz), 4.70 
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(1H, m).  13C NMR (100 MHz, CDCl3) δ 14.32, 19.01, 25.45, 28.32, 28.54, 35.47, 
60.60, 79.64, 154.87, 171.55. 
N
Boc
O
N
MeO
 
(±)-tert-Butyl-2-(2-(methoxy(methyl)amino)-2-oxoethyl)piperidine-1-carboxylate 
(55). Ester 56 (27.5 g, 101 mmol) was dissolved in THF (200 mL) and cooled to an 
internal temperature of -20 ºC. HN(OMe)Me•HCl (15.8 g, 162 mmol) was added to 
the stirring solution resulting in a slurry that was maintained at an internal 
temperature of  -20 ºC. A 2.0 M iPrMgCl solution (152 mL, 304 mmol) was added to 
the slurry over 30 min via syringe pump addition while maintaining the internal 
temperature ≤ -5 ºC during the addition.  Upon complete consumption of starting 
material as determined by TLC (50% EtOAc in hexanes), the reaction was transferred 
to a separatory funnel containing saturated aq. NH4Cl and EtOAc. The layers were 
separated and the aqueous layer was extracted twice more with EtOAc.  The 
combined organic layers were washed with brine, dried over Na2SO4, concentrated, 
and purified by MPLC on silica gel (0-50% acetone in hexanes, 50 min, 210 nm) to 
give 23.3 g of the title compound as a yellow oil (80%). The spectral data are 
consistent with those reported in the literature.56  1H NMR (400 MHz, CDCl3) δ 1.39 
(9H, s), 1.43-1.48 (1H, m), 1.49-1.61 (5H, m), 2.56 (1H, dd, J = 6.7, 13.9 Hz), 2.64 
(1H, dd, J = 8.2, 14.0 Hz), 2.77 (1H, t, J = 12.9 Hz), 3.11 (3H, s), 3.65 (3H, s), 3.94 
(1H, d, J = 11.92 Hz), 4.68 (1H, br s).  13C NMR (100 MHz, CDCl3) δ 19.02, 25.38, 
28.43, 32.12, 32.83, 39.38, 47.70, 61.30, 79.32, 154.81, 172.26. IR (neat, NaCl): 
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2935, 1689, 1665, 1411, 1365, 1164 cm-1.  HRMS (ESI+): m/z calc’d for 
C14H26N2NaO4, 309.1790; found, 309.1794. 
N
Boc
O
N
MeO
 
(S)-tert-Butyl-2-(2-(methoxy(methyl)amino)-2-oxoethyl)piperidine-1-carboxylate 
(58). To a stirring solution of commercially available (S)-2-(1-(tert-
butoxycarbonyl)piperidin-2-yl)acetic acid (4.00 g, 16.5 mmol) in CH2Cl2 (30 mL) 
cooled to 0 °C were added HN(OMe)Me•HCl (1.82 g, 18.2 mmol), NMM (2.00 mL, 
18.2 mmol), and EDCI (3.52 g, 18.2 mmol) in sequence and the reaction was allowed 
to warm to room temperature overnight.  The reaction mixture was transferred to a 
separatory funnel containing 10% aq. HCl and CH2Cl2.  The layers were separated 
and the aqueous layer was extracted twice more with CH2Cl2.  The combined organic 
layers were washed with saturated aq. NaHCO3; the layers were separated and the 
aqueous layers were extracted with CH2Cl2.  The combined organic layers were dried 
over Na2SO4, concentrated, and purified by MPLC on silica gel (0-50% acetone in 
hexanes, 50 min, 210 nm) to give 4.53 g of the title compound as a yellow oil (96%). 
The spectral data are consistent with those reported in the literature.56 1H NMR (400 
MHz, CDCl3) δ 1.43 (9H, s), 1.47-1.52 (1H, m), 1.52-1.65 (5H, m), 2.61 (1H, dd, J = 
6.6, 13.8 Hz), 2.69 (1H, dd, J = 8.3, 14.0 Hz), 2.82 (1H, t, J = 12.9 Hz), 3.15 (3H, s), 
3.69 (3H, s), 3.98 (1H, d, J = 11.9 Hz), 4.72 (1H, br s).  13C NMR (100 MHz, CDCl3) 
δ 19.13, 25.49, 28.55, 32.25, 32.95, 39.51, 47.88, 61.41, 79.47, 154.94, 172.43.  IR 
(neat, NaCl): 2936, 1690, 1666, 1411, 1365, 1164 cm-1. 
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CHCl3).  HRMS (ESI+): m/z calc’d for C14H26N2NaO4, 309.1790; found, 309.1789. 
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(R)-tert-Butyl-2-(2-(methoxy(methyl)amino)-2-oxoethyl)piperidine-1-carboxylate 
(59).  The identical procedure for the synthesis of amide 58 was used employing the 
following amounts; (R)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid (4.00 g, 
16.5 mmol ), CH2Cl2 (30 mL), HN(OMe)Me•HCl (1.82 g, 18.2 mmol), NMM (2.00 
mL, 18.2 mmol), and EDCI (3.52 g, 18.2 mmol), to afford 4.62 g of the title 
compound as a yellow oil (98%). The spectral data are consistent with those reported 
in the literature.56 1H NMR (400 MHz, CDCl3) δ 1.38 (9H, s), 1.42-1.51 (1H, m), 
1.54-1.60 (5H, m), 2.56 (1H, dd, J = 6.80, 13.89 Hz), 2.62 (1H, dd, J = 8.24, 14.01 
Hz), 2.77 (1H, t, J = 12.86 Hz), 3.00 (3H, s), 3.64 (3H, s), 3.93 (1H, d, J = 12.00 Hz), 
4.67 (1H, br s). 13C NMR (100 MHz, CDCl3) δ 19.00, 25.37, 38.42, 32.11, 32.82, 
39.37, 47.74, 61.29, 79.32, 154.81, 172.27. IR (neat, NaCl) 2936, 1689, 1665, 1410, 
1365, 1164. 
! 
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=  7.54 (c = 1.14, CHCl3).  HRMS (ESI+): m/z calc’d for 
C14H26N2NaO4, 309.1790; found, 309.1786. 
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(±)-tert-Butyl-2-(2-oxobut-3-ynyl)piperidine-1-carboxylate (60). To a stirring 
solution of amide 55 (23.3 g, 81.2 mmol) in THF (15 mL) cooled to -78 °C was 
added ethynylmagnesium bromide (0.5 M, 650 mL, 325 mmol) over 30 min.  Thirty 
minutes after complete addition, the reaction mixture was warmed to room 
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temperature.  Following complete consumption of starting material as determined by 
TLC (50% EtOAc in hexanes), the reaction mixture was transferred to a flask 
containing 1 M aq. NaHSO4 (1 L) cooled to 0 °C and stirred for 1 h.  The solution 
was transferred to a separatory funnel and extracted twice with EtOAc.  The 
combined organic layers were washed with aq. saturated NaHCO3, brine, dried over 
Na2SO4, concentrated, and purified by MPLC on silica gel (0-50% acetone in 
hexanes, 50 min, 210 nm) to give 16.4 g of the title compound as a white solid (80%). 
The spectral data are consistent with those reported in the literature.56 1H NMR (400 
MHz, CDCl3) δ 1.44 (9H, s), 1.47-1.55 (2H, m), 1.59-1.72 (4H, m), 2.74-2.81 (2H, 
m), 2.86 (1H, dd, J = 7.1, 14.4 Hz), 3.25 (1H, s), 4.00 (1H, d, J = 10.7 Hz), 4.83 (1H, 
br s).  13C NMR (100 MHz, CDCl3) δ 19.00, 25.32, 28.50, 28.62, 39.33, 46.02, 47.61, 
78.98, 80.04, 81.71, 154.73, 185.21.  IR (neat, NaCl): 3212, 2936, 2090, 1679, 1411, 
1366, 1165 cm-1.  MP = 60-62 °C.  HRMS (ESI+): m/z calc’d for C14H21NNaO3, 
274.1419; found 274.1416. 
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(S)-tert-Butyl-2-(2-oxobut-3-ynyl)piperidine-1-carboxylate (61). The identical 
procedure for the synthesis of ynone 58 was used employing the following amounts; 
amide 58 (4.43 g, 15.5 mmol), THF (40 mL), ethynylmagnesium bromide (0.5 M, 
124 mL, 62.0 mmol), 1 M aq. NaHSO4 (500 mL) to give 3.52 g of the title compound 
as a white solid (91%). The spectral data are consistent with those reported in the 
literature.56  1H NMR (400 MHz, CDCl3) δ 1.44 (9H, s), 1.46-1.55 (2H, m), 1.59-1.72 
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(4H, m), 2.74-2.81 (2H, m), 2.86 (1H, dd, J = 7.0, 14.3 Hz), 3.25 (1H, s), 4.00 (1H, d, 
J = 11.0 Hz), 4.83 (1H, br s).  13C NMR (100 MHz, CDCl3) δ 19.00, 25.32, 28.49, 
28.63, 39.46, 46.02, 47.57, 78.99, 80.04, 81.71, 154.73, 185.22. IR (neat, NaCl): 
3212, 2937, 2091, 1681, 1412, 1366, 1166 cm-1.  MP = 71-73 °C. 
! 
"[ ]
D
25
=  +45.6 (c = 
0.563, CHCl3).  HRMS (ESI+): m/z calc’d for C14H21NNaO3, 274.1419; found 
274.1417. 
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(R)-tert-Butyl-2-(2-oxobut-3-ynyl)piperidine-1-carboxylate (62).  The identical 
procedure for the synthesis of ynone 61 was used employing the following amounts; 
amide 59 (4.36 g, 15.2 mmol), THF (45 mL), ethynylmagnesium bromide (122 mL, 
60.9 mmol), 1 M aq. NaHSO4 (500 mL) to give 3.43 g of the title compound as a 
white solid (90%). The spectral data are consistent with those reported in the 
literature.56  1H NMR (400 MHz, CDCl3) δ 1.44 (9H, s), 1.46-1.55 (2H, m), 1.58-1.71 
(4H, m), 1.64-1.72 (2H, m), 2.73-2.77 (1H, m), 2.77-2.80 (1H, m), 2.85 (1H, dd, J = 
7.1, 14.4 Hz), 3.26 (1H, s), 4.00 (1H, d, J = 10.88 Hz), 4.82 (1H, br s).  13C NMR 
(400 MHz, CDCl3) δ 18.99, 25.31, 28.48, 28.61, 39.33, 46.01, 47.52, 79.00, 80.03, 
81.70, 154.72, 185.20. IR (neat, NaCl): 2937, 2091, 1682, 1412, 1366, 1166. MP = 
71-73 °C.  
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=  -44.2  (c = 0.740, CHCl3).  HRMS (ESI+): m/z calc’d for 
C14H21NNaO3, 274.1419; found 274.1414. 
 
 72 
N
O
 
(±)-7,8,9,9a-Tetrahydro-1H-quinolizin-2(6H)-one (54). To a round-bottomed flask 
containing ynone 60 (13.3 g, 52.8 mmol) and NaI (23.7 g, 158 mmol) was added 
formic acid (500 mL) and the reaction was stirred under an ambient atmosphere 
overnight.  The resulting reaction mixture was concentrated to dryness and methanol 
(820 mL) and K2CO3 (3.43 g, 24.6 mmol) were added in sequence to the flask and the 
reaction mixture was stirred overnight at ambient temperature.  The resulting solution 
was concentrated, dry-loaded onto silica gel, and purified by MPLC on silica gel (15-
65% acetone in hexanes, 50 min, 210 nm) to give 6.02 g of the title compound as a 
yellow solid (92%). The spectral data are consistent with those reported in the 
literature.56  1H NMR (400 MHz, CDCl3) δ 1.38 (1H, dddd, J = 3.2, 6.5, 12.5, 15.9 
Hz), 1.45-1.54 (1H, m), 1.55-1.64 (1H, m), 1.71-1.79 (2H, m), 1.82-1.89 (1H, m), 
2.36 (1H, dd, J = 13.1, 16.4), 2.47 (1H, dd, J = 5.6, 16.4 Hz), 2.98 (1H, dt, J = 3.0, 
12.6 Hz), 3.26-3.34 (1H, m), 3.36-3.40 (1H, m), 4.98 (1H, d, J = 7.0 Hz), 6.86 (1H, d, 
J = 7.6 Hz).  13C NMR (100 MHz, CDCl3) δ 23.33, 25.77, 31.85, 43.40, 53.15, 57.33, 
99.62, 154.97, 192.55.  IR (neat, NaCl): 2938, 1634, 1587, 1446, 1389, 1324, 1237, 
1143 cm-1.  MP = 67-69 °C.  HRMS (ESI+): m/z calc’d for C9H13NNaO, 174.0895; 
found 174.0893. 
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(S)-7,8,9,9a-Tetrahydro-1H-quinolizin-2(6H)-one (63). The identical procedure for 
the synthesis of enaminone 54 was used employing the following amounts; ynone 61 
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(1.99 g, 7.96 mmol), NaI (3.60 g, 23.9 mmol), formic acid (40 mL); MeOH (800 mL) 
and K2CO3 (3.30 g, 23.9 mmol) to give 1.13 g of the title compound as a white solid 
(94%). The spectral data are consistent with those reported in the literature.56  1H 
NMR (400 MHz, CDCl3) δ 1.35 (1H, dddd, J = 3.0, 6.4, 12.4, 15.8 Hz), 1.43-1.50 
(1H, m), 1.52-1.61 (1H, m), 1.70-1.76 (2H, m), 1.79-1.86 (1H, m), 2.32 (1H, dd, J = 
13.1, 16.4 Hz), 2.44 (1H, dd, J = 5.6, 16.4 Hz), 2.95 (1H, dt, J = 3.0, 12.7 Hz), 3.23-
3.31 (1H, m), 3.34-3.38 (1H, m), 4.94 (1H, d, J = 7.6 Hz), 6.84 (1H, d, J = 7.6 Hz).  
13C NMR (100 MHz, CDCl3) δ 23.24, 25.69, 31.76, 43.30, 53.06, 57.22, 99.45, 
154.93, 192.44. IR (neat, NaCl): 2940, 1631, 1581, 1239, 1143 cm-1.  MP = 47-49 °C. 
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=  +145 (c = 1.15, CHCl3), HRMS (ESI+): m/z calc’d for C9H13NNaO, 174.0895; 
found 174.0884. 
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(R)-7,8,9,9a-Tetrahydro-1H-quinolizin-2(6H)-one (64). The identical procedure for 
the synthesis of enaminone 54 was used employing the following amounts; ynone 62 
(2.02 g, 7.96 mmol), NaI (3.63 g, 23.9 mmol), formic acid (40 mL); MeOH (800 mL) 
and K2CO3 (3.3 g, 23.9 mmol) to give 1.08 g of the title compound as a white solid 
(90 %). The spectral data are consistent with those reported in the literature.56  1H 
NMR (400 MHz, CDCl3) δ 1.37 (1H, dddd, J = 3.1. 6.4, 12.4, 15.9 Hz), 1.44-1.52 
(1H, m), 1.58 (1H, dddd, J = 4.2, 7.9, 12.8, 26.0 Hz), 1.70-1.78 (2H, m), 1.81-1.88 
(1H, m), 2.34 (1H, dd, J = 13.1, 16.4 Hz), 2.46 (1H, dd, J = 5.6, 16.4 Hz), 2.97 (1H, 
dt, J = 3.0, 12.6 Hz), 3.24-3.32 (1H, m), 3.35-3.39 (1H, m), 4.96 (1H, d, J = 7.6 Hz), 
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6.85 (1H, d, J = 7.6 Hz).  13C NMR (400 MHz, CDCl3) δ 23.29, 25.73, 31.81, 43.33, 
53.11, 57.27, 99.51, 154.98, 192.52. IR (neat, NaCl): 3449 (br), 2938, 1637, 1588, 
1444, 1237.  MP = 47-49 °C. 
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25
=  -140 (c = 1.20, CHCl3).  HRMS (ESI+): m/z 
calc’d for C9H13NNaO, 174.0895; found 174.0893. 
BF3K
OMe
OMe  
Potassium 3,4-Dimethoxyphenyltrifluoroborate (65). 3,4-Dimethoxyphenylboronic 
acid (2.00 g, 11.0 mmol) and KHF2 (2.00 g, 25.3 mmol) were combined in a 
MeOH/H2O (60 mL) solution in a polypropylene screw-top vessel and placed on an 
orbital shaker overnight at room temperature.  The resulting slurry was  concentrated 
to dryness and subsequently dissolved in hot acetone and filtered.  The filtrate was  
concentrated until the trifluoroborate was sparingly soluble.  The solution was gently 
heated and Et2O was  added resulting in a white precipitate that was cooled to 4 °C 
overnight.  The heterogeneous solution was filtered and the resulting solid was 
washed with Et2O and dried to afford 2.56 g of the title compound as a white solid 
(96%).  1H NMR (400 MHz, d6-DMSO) δ 3.66 (3H, s), 3.67 (3H, s), 6.69 (1H, d, J = 
7.8 Hz), 6.83 (1H, d, J = 7.8 Hz), 6.87 (1H, s).  13C NMR (100 MHz, d6-DMSO) δ 
55.11, 55.41, 110.91, 115.10 (1C, d, J = 1.2 Hz), 123.51 (d, 1C, J = 1.3 Hz), 146.69, 
147.46.  19F NMR (376.4 MHz, d6-DMSO, CFCl3 internal std) δ -137.89. CHN: 
calc’d for C8H9BF3KO2, C, 39.37; H, 3.72; found: C, 38.98; H, 3.89.   
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(±)-3-(3,4-Dimethoxyphenyl)-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (53). 
Enaminone 54 (749 mg, 4.95 mmol), [Pd(OAc)2]3 (334 mg, 0.50 mmol), anhydrous 
Cu(OAc)2 (2.74 g, 14.9 mmol), and K2CO3 (1.37 g, 9.90 mmol) were combined in a 
tBuOH/AcOH/DMSO solution (20:5:1, 50 mL) and stirred for 5 min.  The reaction 
mixture was heated to 60 °C and potassium 3,4-dimethoxyphenyltrifluoroborate (2.42 
g, 9.90 mmol) in acetone/H2O (2:1, 20 mL) was added to the reaction mixture over 1 
h. An additional portion of [Pd(OAc)2]3 (168 mg, 0.25 mmol) was  added to the 
stirring mixture and the remaining potassium 3,4-dimethoxyphenyltrifluoroborate 
(2.42 g, 9.90 mmol) in acetone/H2O (2:1, 20 mL) was added to the reaction mixture 
over 1 h.  The reaction mixture was cooled room temperature and K2CO3 was added 
to the dark reaction medium until gas evolution ceased.  The basic solution was 
filtered through a celite plug eluting with EtOAc, concentrated, and purified by 
MPLC on silica gel (15-65% acetone in hexanes, 50 min, 210 nm) to give 1.19 g of 
the title compound as a white solid (83%).  1H NMR (400 MHz, CDCl3) δ 1.41 (1H, 
dddd, J = 3.0, 6.2, 12.3, 19.2 Hz), 1.48-1.60 (1H, m), 1.61-1.70 (1H, m), 1.77-1.86 
(2H, m), 1.87-1.92 (1H, m), 2.51 (1H, dd, J = 13.3, 16.2 Hz), 2.61 (1H, dd, J = 5.4, 
16.2 Hz), 3.06 (1H, dt, J = 3.0, 12.7 Hz), 3.34-3.42 (1H, m), 3.44-3.48 (1H, m), 3.86 
(3H, s), 3.88 (3H, s), 6.82 (1H, d, J = 8.3 Hz), 6.85 (1H, dd, J = 1.8, 8.3 Hz), 7.02 
(1H, d, J = 1.8 Hz), 7.10 (1H, s).  13C NMR (100 MHz, CDCl3) δ 23.26, 25.82, 31.83, 
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44.07, 53.31, 56.00, 56.10, 57.39, 111.29, 112.05, 112.27, 119.72, 129.20, 147.48, 
148.66, 153.72, 189.90. IR (neat, NaCl): 2936, 1634, 1595, 1515, 1251, 1028 cm-1.  
MP = 123-125 °C.  HRMS (ESI+): m/z calc’d for C17H22NO3, 288.1600; found 
288.1598. 
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 (S)-3-(3,4-Dimethoxyphenyl)-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (66). 
The identical procedure for the synthesis of quinolizidone 53 was used employing the 
following amounts; enaminone 63  (301 mg, 1.98 mmol), [Pd(OAc)2]3 (133 mg, 0.20 
mmol and 67 mg, 0.1 mmol), anhydrous Cu(OAc)2 (1.08 g, 5.94 mmol), K2CO3 (551 
mg, 3.96 mmol), tBuOH/AcOH/DMSO (20:5:1, 18 mL), two portions of potassium 
3,4-dimethoxyphenyltrifluoroborate (1.0 g, 4.1 mmol) in acetone/H2O (2:1, 7.5 mL) 
to give 415 mg of the title compound as a white solid (73%).  1H NMR (400 MHz, 
CDCl3) δ 1.41 (1H, dddd, J = 2.9, 6.1, 12.3, 19.0 Hz), 1.48-1.58 (1H, m), 1.59-1.69 
(1H, m), 1.77-1.85 (2H, m), 1.86-1.90 (1H, m), 2.51 (1H, dd, J = 13.3, 16.1 Hz), 2.61 
(1H, dd, J = 5.4, 16.2 Hz), 3.05 (1H, dt, J = 3.0, 12.7 Hz), 3.34-3.42 (1H, m), 3.44-
3.48 (1H, m), 3.85 (3H, s), 3.88 (3H, s), 6.81 (1H, d, J = 8.3 Hz), 6.86 (1H, dd, J = 
1.8, 8.3 Hz), 7.02 (1H, d, J = 1.7 Hz), 7.08 (1H, s).  13C NMR (100 MHz, CDCl3) δ 
23.23, 25.79, 31.81, 44.03, 53.28, 55.97, 56.08, 57.35, 111.27, 112.03, 112.21, 
119.70, 129.18, 147.44, 148.62, 153.73, 189.89. IR (neat, NaCl): 3468 (br), 2935, 
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1634, 1595, 1515, 1251, 1027 cm-1.  MP = 112-114 °C. 
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=  +5.96 (c = 1.14, 
CHCl3).  HRMS (ESI+): m/z calc’d for C17H22NO3, 288.1600; found 288.1592. 
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(R)-3-(3,4-Dimethoxyphenyl)-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (67).  
The identical procedure for the synthesis of quinolizidone 53 was used employing the 
following amounts; enaminone 64 (366 mg, 2.42 mmol), [Pd(OAc)2]3 (163 mg, 0.24 
mmol and 81 mg, 0.12), anhydrous Cu(OAc)2 (1.22 g, 6.72 mmol), K2CO3 (670 g, 
4.84 mmol), tBuOH/AcOH/DMSO (20:5:1, 15 mL), two portions of potassium 3,4-
dimethoxyphenyltrifluoroborate (1.18 g, 4.85 mmol) in acetone/H2O (2:1, 8 mL). to 
give 526 mg of the title compound as a white solid (75%).1H NMR (400 MHz, 
CDCl3) δ 1.40 (1H, dddd, J = 2.9, 6.2, 12.2, 19.1 Hz), 1.48-1.57 (1H, m), 1.57-1.67 
(1H, m), 1.76-1.85 (2H, m), 1.86-1.91 (1H, m),  2.50 (1H, dd, J = 13.3, 16.2 Hz), 
2.60 (1H, dd, J = 5.4, 16.2 Hz), 3.05 (1H, dt, J = 2.99, 12.69 Hz), 3.33-3.41 (1H, m), 
3.44-3.48 (1H, m), 3.85 (3H, s), 3.88 (3H, s), 6.81 (1H, d, J = 8.3 Hz), 6.85 (1H, dd, J 
= 1.8, 8.3 Hz), 7.02 (1H, d, J = 1.76 Hz), 7.08 (1H, s).  13C NMR (100 MHz, CDCl3) 
δ 23.22, 25.78, 31.80, 44.03, 53.28, 55.97, 56.07, 57.34, 111.26, 112.02, 112.20, 
119.69, 129.18, 147.71, 148.62, 153.71, 189.86. IR (neat, NaCl): 2936, 1595, 1514, 
1250, 1027.  MP = 112-114 °C. 
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=  -6.60 (c = 0.773, CHCl3).  HRMS (ESI+): m/z 
calc’d for C17H22NO3, 288.1600; found 288.1590. 
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(±)-3-(3,4-Dimethoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizin-2-yl 
Trifluoromethanesulfonate (75). Quinolizidone 53  (300 mg, 1.04 mmol) was 
dissolved in THF (3 mL) and cooled to -78 °C.  L-Selectride (1.0 M, 1.04 mL, 1.04 
mmol) was added dropwise to the stirring solution and the reaction was maintained at 
-78 °C for 30 min at which time the solution was warmed to room temperature. 
Comins’ reagent (74, 494 mg, 1.25 mmol) was subsequently added to the reaction 
mixture and allowed to stir at room temperature overnight.  The resulting solution 
was quenched with saturated aq. NaHCO3 (1.0 mL), diluted with CH2Cl2 (3.0 mL), 
dried with K2CO3, and filtered through celite.  The resulting filtrate was concentrated 
and purified by MPLC on silica gel (15-55% EtOAc in hexanes with 1% TEA, 40 
min, 254 nm) to afford the title compound as a red-brown oil (81%).  1H NMR (400 
MHz, CDCl3) δ 1.28-1.32 (1H, m), 1.34-1.45 (1H, m), 1.60-1.73 (2H, m), 1.78-1.81 
(1H, m), 1.84-1.87 (1H, m), 2.10 (1H, dt, J = 3.2, 11.7 Hz), 2.35-2.44 (1H, m), 2.47-
2.54 (2H, m), 3.03-3.06 (1H, m), 3.11 (1H, td, J = 3.3, 16.4 Hz), 3.56 (1H, d, J = 
16.4 Hz), 3.86 (3H, s), 3.88 (3H, s), 6.81-6.85 (3H, m).  13C NMR (100 MHz, CDCl3) 
δ 23.71, 25.68, 33.05, 35.73, 54.94, 55.97, 56.02, 57.83, 59.17, 111.07, 111.73, 
118.22 (1C, q, J = 320.0 Hz), 120.72, 126.59, 128.00, 140.39, 148.86, 149.16. IR 
(neat, NaCl): 2936, 1519, 1414, 1211, 1141, 1031 cm-1. HRMS (ESI+): m/z calc’d for 
C18H23F3NO5S3, 422.1249; found 422.1248. 
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(S)-3-(3,4-Dimethoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizin-2-yl 
Trifluoromethanesulfonate (76). The identical procedure for the synthesis of triflate 
75 was used employing the following amounts; quinolizidone 65 (312 mg, 1.10 
mmol), THF (5 mL), L-Selectride (1.0 M, 1.1 mL, 1.1 mmol), Comins’ reagent (514 
mg, 1.3 mmol) to yield 333 mg of the title compound as a red-brown oil (72%).  1H 
NMR (400 MHz, CDCl3) δ 1.24-1.27 (1H, m), 1.29-1.32 (1H, m), 1.58-1.68 (2H, m), 
1.72-1.75 (1H, m), 1.78-1.81 (1H, m), 2.05 (1H, dt, J = 2.9, 11.6 Hz), 2.33-2.37 (1H, 
m), 2.42-2.49 (2H, m), 2.98-3.00 (1H, m), 3.04-3.08 (1H, m), 3.54 (1H, d, J = 16.4 
Hz), 3.80 (3H, br s), 3.81 (3H, br s), 6.77-6.82 (3H, m).  13C NMR (100 MHz, CDCl3) 
δ 23.70, 25.68, 33.06, 35.74, 54.91, 55.93, 55.98, 57.79, 59.17, 111.04, 111.70, 
118.19 (1C, q, J = 320 Hz), 120.68, 126.60, 128.00, 140.39, 148.82, 149.12.  IR 
(neat, NaCl): 2936, 1519, 1415, 1210, 1141, 1030 cm-1. 
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=  +57 (c = 0.60, 
CHCl3).  HRMS (ESI+): m/z calc’d for C18H23F3NO5S3, 422.1249; found 422.1262. 
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(R)-3-(3,4-Dimethoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizin-2-yl 
Trifluoromethanesulfonate (77). The identical procedure for the synthesis of triflate 
75 was used employing the following amounts; quinolizidone 66 (526 mg, 1.83 
mmol), THF (12 mL), L-Selectride (1.0 M, 1.9 mL, 1.88 mmol), Comins’ reagent 
(935 mg, 2.38 mmol) to yield 591 mg of the title compound as a red-brown oil (77%).  
1H NMR (400 MHz, CDCl3) δ   1.23-1.28 (1H, m), 1.30-1.36 (1H, m), 1.59-1.70 (2H, 
m), 1.73-1.76 (1H, m), 1.80-1.82 (1H, m), 2.05 (1H, dt, J = 2.9, 11.6 Hz), 2.33-2.36 
(1H, m), 2.40-2.50 (2H, m), 2.98-3.01 (1H, m), 3.05-3.09 (1H, m), 3.54 (1H, d, J = 
16.4 Hz), 3.82 (3H, br s), 3.83 (3H, br s), 6.80-6.83 (3H, m).    13C NMR (100 MHz, 
CDCl3) δ 23.72, 25.70, 33.08, 35.76, 54.94, 55.96, 56.01, 57.81, 59.20, 111.06, 
111.72, 118.21 (1C, q, J = 320 Hz), 120.70, 126.62, 128.01, 140.41, 148.84, 149.14.  
IR (neat, NaCl): 2936, 1519, 1415, 1210, 1141, 1030 cm-1. 
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=  -49 (c = 0.97, 
CHCl3).  HRMS (ESI+): m/z calc’d for C18H23F3NO5S3, 422.1249; found 422.1239. 
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(±)-7-(3,4-Dimethoxyphenyl)-2,3,4,6,9,9a-hexahydro-1H-quinolizine (78).  
Typical experimental procedure used for Suzuki coupling:  Triflate 75 (1 equiv), 
Pd(OAc)2 (10 mol%), S-Phos (20 mol%), potassium 4-methoxyphenyltrifluoroborate 
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(1.5 equiv), K2CO3 were dissolved in degassed HPLC  grade MeOH and heated to 60 
°C overnight.  The resulting reaction mixture was  immediately purified by MPLC to 
give the side-product 77 in variable yields as a brown solid.  1H NMR (400 MHz, 
CDCl3) δ 1.28-1.36 (2H, m), 1.68-1.72 (2H, m), 1.78-1.81 (2H, m), 2.12-2.28 (4H, 
m), 3.02-3.10 (2H, m), 3.62-3.65 (1H, m), 3.86 (3H, s), 3.88 (3H, s), 5.94-5.95 (1H, 
m), 6.79-6.81 (1H, m), 6.85-6.88 (2H, m).  13C NMR (100 MHz, CDCl3) δ 24.47, 
25.95, 33.43, 34.09, 55.96, 56.01, 56.21, 56.93, 57.20, 108.77, 111.01, 117.50, 
120.79, 133.28, 134.40, 148.37, 148.82.  IR (neat, NaCl): 2926, 1600, 1581, 1519, 
1166, 1147, 1028, 805 cm-1. MP = 114-116 °C. HRMS (ESI+): m/z calc’d for 
C17H24NO2, 274.1801; found 274.1807. 
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(±)-7-(3,4-Dimethoxyphenyl)-8-(4-methoxyphenyl)-2,3,4,6,9,9a-hexahydro-1H-
quinolizine (80). A reaction vessel containing ZnBr2 (297 mg, 1.32 mmol) was 
flame-dried under vacuum and upon reaching room temperature it was released from 
vacuum and fitted immediately with a septum and placed under a nitrogen 
atmosphere. THF (4 mL) was added to the purged reaction vessel and once 
homogeneity was achieved, 4-methoxyphenylmagnesium bromide (0.5 M in THF, 2.2 
mL, 1.11 mmol) was added, resulting in a white slurry that was stirred for 10 min.  
This solution was transferred to a reaction vessel containing triflate 75 (155 mg, 0.37 
mmol) and Pd(PPh3)4 (48 mg, 0.04 mmol) and the reaction mixture was  heated to 60 
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°C.  Monitoring by TLC (50% EtOAc in hexanes with 1% TEA) showed complete 
consumption of starting material within 1 h.  The reaction was  allowed to cool to 
room temperature and immediately purified by MPLC on silica gel (25-75% EtOAc 
in hexanes with 1% TEA, 50 min, 254 nm) to give 135 mg of the title compound as a 
tan foam (97%).  1H NMR (400 MHz, CDCl3) δ 1.31-1.39 (2H, m), 1.66-1.74 (2H, 
m), 1.79-1.85 (2H, m), 2.08-2.14 (1H, m), 2.30-2.32 (1H, m), 2.34-2.42 (1H, m), 
2.49-2.53 (1H, m), 3.02-3.11 (2H, m), 3.56 (3H, s), 3.63 (1H, d, J = 16.5 Hz), 3.71 
(3H, s), 3.80 (3H, s), 6.47 (1H, m), 6.62-6.64 (4H, m), 6.92 (2H, m).  13C NMR (100 
MHz, CDCl3) δ 24.36, 25.90, 33.32, 39.82, 55.09, 55.51, 55.60, 55.67, 57.90, 60.11, 
110.52, 113.19, 113.24, 120.86, 129.80, 131.23, 131.41, 133.26, 134.37, 147.34, 
148.04, 157.84.  IR (neat, NaCl): 2930, 1606, 1511, 1246, 1030, 755 cm-1. HRMS 
(ESI+): m/z calc’d for C24H29NO3, 380.2232; found 380.2226.  
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(S)-7-(3,4-Dimethoxyphenyl)-8-(4-methoxyphenyl)-2,3,4,6,9,9a-hexahydro-1H-
quinolizine (81). The identical procedure for the synthesis of quinolizine 80 was used 
employing the following amounts; ZnBr2 (160 mg, 0.71 mmol), 4-
methoxyphenylmagnesium bromide (0.5 M in THF, 1.2 mL, 0.60 mmol), THF (2 
mL), triflate 76 (84 mg, 0.20 mmol), and Pd(PPh3)4 (23 mg, 0.02 mmol) to give 70 
mg of the title compound as a tan foam (92%).  1H NMR (400 MHz, CDCl3) δ 1.31-
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1.39 (2H, m), 1.70-1.73 (2H, m), 1.80-1.86 (2H, m), 2.08-2.15 (1H, m), 2.30-2.32 
(1H, m), 2.35-2.41 (1H, m), 2.48-2.54 (1H, m), 3.02-3.11 (2H, m), 3.56 (3H, s), 3.63 
(1H, d, J = 16.6 Hz), 3.72 (3H, s), 3.81 (3H, s), 6.49 (1H, m), 6.64-6.69 (4H, m), 
6.92-6.97 (2H, m).  13C NMR (100 MHz, CDCl3) δ 24.51, 26.05, 33.46, 39.96, 55.27, 
55.67, 55.76, 55.83, 58.06, 60.27, 110.65, 113.32, 113.39, 121.00, 129.95, 131.38, 
131.57, 133.42, 134.53, 147.48, 148.18, 157.97. IR (neat, NaCl): 2930, 1606, 1511, 
1245, 1030, 755 cm-1. 
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=  160 (c = 0.98, CHCl3).  HRMS (ESI+): m/z calc’d for 
C24H29NO3, 380.2226; found 380.2229. 
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(R)-7-(3,4-Dimethoxyphenyl)-8-(4-methoxyphenyl)-2,3,4,6,9,9a-hexahydro-1H-
quinolizine (82). The identical procedure for the synthesis of quinolizine 80 was used 
employing the following amounts; ZnBr2 (365 mg, 1.6 mmol), 4-
methoxyphenylmagnesium bromide (0.5 M in THF, 2.8 mL, 1.4 mmol), THF (5 mL), 
triflate 77 (195 mg, 0.46 mmol), and Pd(PPh3)4 (58 mg, 0.05 mmol) to give 176 mg of 
the title compound as a tan foam (99%).  1H NMR (400 MHz, CDCl3) δ 1.32-1.38 
(2H, m), 1.67-1.76 (2H, m), 1.79-1.85 (2H, m), 2.08-2.15 (1H, m), 2.30-2.32 (1H, m), 
2.35-2.41 (1H, m), 2.49-2.53 (1H, m), 3.03-3.11 (2H, m), 3.56 (3H, s), 3.63 (1H, d, J 
= 16.5 Hz), 3.71 (3H, s), 3.80 (3H, s), 6.49 (1H, s), 6.65-6.67 (4H, m), 6.93-6.95 (2H, 
m).  13C NMR (100 MHz, CDCl3) δ 24.36, 25.90, 33.32, 39.82, 55.09, 55.51, 55.60, 
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55.67, 57.90, 60.11, 110.52, 113.19, 113.24, 120.86, 129.80, 131.23, 131.41, 133.26, 
134.37, 147.34, 148.04, 157.84.  IR (neat, NaCl): 2930, 1606, 1511, 1246, 1030, 756 
cm-1. 
! 
"[ ]
D
25
=  -160 (c = 0.89, CHCl3).  HRMS (ESI+): m/z calc’d for C24H29NO3, 
380.2226; found. 380.2233. 
N
MeO
MeO
OMe  
(±)-Boehmeriasin A (1). Quinolizine 80 (105 mg, 0.28 mmol) in CH2Cl2 (25 mL) 
was cooled to -78 °C under a nitrogen atmosphere. VOF3 (73 mg, 0.59 mmol) in a 
solution of TFA/CH2Cl2/EtOAc (1:1:1, 6 mL) was subsequently added to the stirring 
solution in one portion at -78 °C.  The reaction was monitored by TLC (50% EtOAc 
in hexanes with 1% TEA) and complete consumption of starting material was 
observed within 1 h.  The reaction was quenched with 10% aq. NaOH (10 mL) and 
the solution was warmed to room temperature.  The layers were separated and the 
aqueous phase was extracted CH2Cl2 (2×).  The combined organic extracts were dried 
with Na2SO4, concentrated, and purified by MPLC on silica gel (35-85% EtOAc in 
hexanes with 1% TEA, 50 min, 254 nm) to give 101 mg of the title compound as a 
white solid (97%).  1H NMR (400 MHz, CDCl3) δ 1.39-1.45 (1H, m), 1.48-1.55 (1H, 
m), 1.71-1.80 (2H, m), 1.86 (1H, m), 1.96-2.00 (1H, m), 2.23-2.27 (1H, m), 2.29-2.32 
(1H, m), 2.85-2.91 (1H, m), 3.11 (1H, dd, J = 2.9 Hz), 3.26 (1H, d, J = 11.0 Hz), 3.51 
(1H, d, J = 15.2 Hz), 3.99 (3H, s), 4.03 (3H, s), 4.08 (3H, s), 4.29 (1H, d, J =15.2 Hz), 
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7.08 (1H, s), 7.18 (1H, dd, J = 2.5 Hz, 9.0 Hz), 7.85-7.87 (3H, m). 13C NMR (100 
MHz, CDCl3) δ 24.53, 26.16, 33.95, 34.87, 55.66, 56.11, 56.14, 56.36, 56.54, 57.68, 
103.21, 104.17, 104.77, 114.89, 123.40, 124.44, 125.16, 125.35, 126.10, 130.40, 
148.32, 149.53, 157.67.  IR (neat, NaCl): 2928, 2253, 1611, 1511,  1470, 1256, 1204, 
1140, 1040 cm-1. MP = decomp. >214 °C.  HRMS (ESI+): m/z calc’d for C24H29NO3, 
378.2069; found 378.2067. 
N
MeO
MeO
OMe
H
 
(S)-Boehmeriasin A (83). The identical procedure for the synthesis of (±)-
boehmeriasin A (1) was used employing the following amounts; quinolizine 81 (76 
mg, 0.20 mmol), CH2Cl2 (17 mL), VOF3 (55 mg, 0.44 mmol),TFA/CH2Cl2/EtOAc 
(1:1:1, 3 mL) to give 56 mg of the title compound as a white solid (74%).  1H NMR 
(400 MHz, CDCl3) δ 1.39-1.45 (1H, m), 1.48-1.55 (1H, m), 1.71-1.80 (2H, m), 1.86 
(1H, m), 1.96-2.00 (1H, m), 2.23-2.27 (1H, m), 2.29-2.31 (1H, m), 2.84-2.91 (1H, m), 
3.09 (1H, dd, J = 2.9 Hz), 3.25 (1H, d, J = 11.0 Hz), 3.50 (1H, d, J = 15.2 Hz), 3.98 
(3H, s), 4.03 (3H, s), 4.07 (3H, s), 4.28 (1H, d, J = 15.2 Hz), 7.07 (1H, s), 7.17 (1H, 
dd, J = 2.3, 9.0 Hz), 7.84-7.86 (3H, m). 13C NMR (100 MHz, CDCl3) δ 24.52, 26.16, 
33.94, 34.85, 55.65, 56.10, 56.12, 56.33, 56.53, 57.64, 103.19, 104.14, 104.74, 
114.87, 123.39, 124.41, 125.14, 125.34, 126.07, 130.39, 148.30, 149.51, 157.66.  IR 
(neat, NaCl): 2932, 2252, 1612, 1513, 1470, 1256, 1204, 1141, 1041, 730  cm-1. 
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D
25
=  +73 (c = 0.14, MeOH) (Note: compound is sparingly soluble in MeOH). MP = 
decomp. >214 °C.  HRMS (ESI+): m/z calc’d for C24H29NO3, 378.2069; found 
378.2070. Chiral HPLC analysis (Chiralpak AD-H (250 mm x 4.6 mm), 35-80% 
isopropanol in n-heptane, 45 min, 0.5 mL/min, 254 nm, (S)-isomer, tR = 24.2 min, 
(R)-isomer, tR = 32.6 min, er = 97:3). 
N
MeO
MeO
OMe
H
 
(R)-Boehmeriasin A (84). The identical procedure for the synthesis of (±)-
boehmeriasin A (1) was used employing the following amounts; quinolizine 82 (40 
mg, 0.11 mmol), CH2Cl2 (9 mL), VOF3 (30 mg, 0.22 mmol), TFA/CH2Cl2/EtOAc 
(1:1:1, 3 mL) to give 31.2 mg of the title compound as a white solid (83%).  1H NMR 
(400 MHz, CDCl3) δ 1.40-1.47 (1H, m), 1.49-1.56 (1H, m), 1.72-1.80 (2H, m), 1.86 
(1H, m), 1.97-2.00 (1H, m), 2.25-2.29 (1H, m), 2.31-2.35 (1H, m), 2.87-2.93 (1H, m), 
3.09 (1H, dd, J = 2.9 Hz), 3.27 (1H, d, J = 11.0 Hz), 3.53 (1H, d, J = 15.2 Hz), 3.99 
(3H, s), 4.03 (3H, s), 4.08 (3H, s), 4.31 (1H, d, J = 15.2 Hz), 7.09 (1H, s), 7.18 (1H, 
dd, J = 2.5, 9.0 Hz), 7.85-7.87 (3H, m). 13C NMR (100 MHz, CDCl3) δ 24.53, 26.16, 
33.95, 34.87, 55.66, 56.11, 56.14, 56.36, 56.54, 57.68, 103.21, 104.17, 104.77, 
114.88, 123.40, 124.44, 125.16, 125.35, 126.10, 130.40, 148.32, 149.53, 157.66. IR 
(neat, NaCl): 2932, 2253, 1612, 1513, 1470, 1256, 1204, 1140, 1041, 731 cm-1. 
! 
"[ ]
D
25
=  -93 (c = 0.15, CHCl3); 
! 
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D
25
=  -86 (c = 0.10, MeOH) (Note: compound is 
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sparingly soluble in MeOH). MP = decomp. >214 °C.  HRMS (ESI+): m/z calc’d for 
C24H29NO3, 378.2069; found 378.2057. Chiral HPLC analysis (Chiralpak AD-H (250 
mm x 4.6 mm), 35-80% isopropanol in n-heptane, 45 min, 0.5 mL/min, 254 nm, (S)-
isomer, tR = 24.2 min, (R)-isomer, tR = 32.6 min, er = 97:3). 
4.2.2 Biological Evaluation 
Cytotoxicity Assay.130,131   The human cancer cell lines MCF7, NCI-ADR-RES 
(NCI), and COLO-205 (ATCC CCL-222) were grown in normal RPMI 1640 culture 
medium containing 10% fetal bovine serum.  The cells, in exponential-phase 
maintenance culture, were dissociated with 0.25% trypsin and harvested at 125×g for 
5 min.  Trypsin was removed and the cells were resuspended in new culture medium.  
The cell density was adjusted to 1 x 105 and dispensed in triplicate on 96-well plates 
in 50 µL volumes.  After incubation overnight at 37 °C under 5% CO2, 50 µL of 
culture medium containing various concentrations of the test compounds was added. 
Paclitaxel and colchicine were used as positive controls.  After 48 h incubation, the 
relative cell viability in each well was determined by using the AlamarBlue Assay 
Kit. The IC50 of each compound was determined by fitting the relative viability of the 
cells to the drug concentration using a dose-response model. 
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Data collection 
A crystal (approximate dimensions 0.45x 0.23 x 0.12mm3) was placed onto the tip of 
a 0.1 mm diameter glass capillary and mounted on a CCD area detector 
diffractometer for a data collection at173(2) K.1  A preliminary set of cell constants 
was calculated from reflections harvested from three sets of 20 frames.  These initial 
sets of frames were oriented such that orthogonal wedges of reciprocal space were 
surveyed.  This produced initial orientation matrices determined from 110 reflections.  
The data collection was carried out using MoKa radiation (graphite monochromator) 
with a frame time of 30 seconds and a detector distance of 4.9 cm.  A randomly 
oriented region of reciprocal space was surveyed to the extent of one sphere and to a 
resolution of 0.80 Å.  Four major sections of frames were collected with 0.30º steps in 
w at four different f settings and a detector position of -28º in2q.  The intensity data 
were corrected for absorption and decay (SADABS).2  Final cell constants were 
calculated from 2932 strong reflections from the actual data collection after 
integration (SAINT).3  Please refer to Table 1 for additional crystal and refinement 
information. 
 
Structure solution and refinement 
The structure was solved using Bruker SHELXTL4 and refined using Bruker 
SHELXTL.4  The space group P21 was determined based on systematic absences and 
intensity statistics.  A direct-methods solution was calculated which provided most 
non-hydrogen atoms from the E-map.  Full-matrix least squares / difference Fourier 
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cycles were performed which located the remaining non-hydrogen atoms.  All non-
hydrogen atoms were refined with anisotropic displacement parameters.  All 
hydrogen atoms were placed in ideal positions and refined as riding atoms with 
relative isotropic displacement parameters.  The final full matrix least squares 
refinement converged to R1 = 0.0428 and wR2 = 0.1185 (F2, all data). 
 
Structure description 
The structure is the one suggested. This is isostructural to the 09035 structure 
completed on the racemic material in space group P21/c with similar cell constants. In 
that structure the site was occupied with both enantiomers in a 0.69:0.31 ratio. It is no 
surprise that this 97 ee material crystallizes in a similar unit cell lacking the true 
inversion symmetry. One of the two unique molecules does exhibit a few small 
difference Fourier peaks in the region of the chiral center, indicating a possibility of 
some small contamination of the S-isomer, but this cannot modeled in the ~5% range. 
 
Data collection and structure solution were conducted at the X-Ray Crystallographic 
Laboratory, 192 Kolthoff Hall, Department of Chemistry, University of Minnesota.  
All calculations were performed using Pentium computers using the current 
SHELXTL suite of programs.  All publications arising from this report MUST either 
1) include Victor G. Young, Jr. as a coauthor or 2) acknowledge Victor G. Young, Jr. 
and the X-Ray Crystallographic Laboratory.
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Some equations of interest:  
 
Rint = S|Fo2-< Fo2>| / S|Fo2| 
R1 = S||Fo|-|Fc|| / S|Fo| 
wR2 = [S[w(Fo2-Fc2)2] / S[w(Fo2)2]]1/2 
where w = q / [s2(Fo2) + (a*P)2 + b*P + d + e*sin(q)] 
GooF = S = [S[w(Fo2-Fc2)2] / (n-p)]1/2 
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Table 1.  Crystal data and structure refinement for 09047b. 
_____________________________________________________________________ 
Identification code  09047b 
Empirical formula  C24 H27 N O3 
Formula weight  377.47 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 13.378(3) Å a = 90° 
 b = 6.5197(12) Å b = 93.028(3)° 
 c = 22.033(4) Å g = 90° 
Volume 1919.1(6) Å3 
Z 4 
Density (calculated) 1.306 Mg/m3 
Absorption coefficient 0.085 mm-1 
F(000) 808 
Crystal color, morphology Colorless, Plate 
Crystal size 0.45 x 0.23 x 0.12 mm3 
Theta range for data collection 0.93 to 26.39° 
Index ranges -16 £h £ 16,0 £k £ 8,0 £l £ 27 
Reflections collected 18876 
 96 
Independent reflections 4281 [R(int) = 0.0383] 
Observed reflections 3380 
Completeness to theta = 26.39° 99.7%  
Absorption correction Multi-scan 
Max. and min. transmission 0.9898 and 0.9626 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4281 / 1 / 511 
Goodness-of-fit on F2 1.030 
Final R indices [I>2sigma(I)] R1 = 0.0428, wR2 = 0.1058 
R indices (all data) R1 = 0.0617, wR2 = 0.1185 
Absolute structure parameter 1.3(16) 
Largest diff. peak and hole 0.321 and -0.186 e.Å-3 
 97 
Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) 
for 09047b.  Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
_____________________________________________________________________ 
 x y z Ueq 
_____________________________________________________________________ 
O1A 5728(2) 13185(4) 386(1) 34(1) 
O2A 5402(2) 15208(4) 1348(1) 35(1) 
O3A 7473(2) 11505(4) 4272(1) 38(1) 
N1A 8368(2) 4846(4) 1062(1) 32(1) 
C1A 7114(2) 9850(5) 1511(1) 26(1) 
C2A 6675(2) 10553(5) 947(1) 27(1) 
C3A 6136(2) 12326(5) 906(1) 27(1) 
C4A 5963(2) 13466(5) 1442(1) 27(1) 
C5A 6364(2) 12804(6) 1990(1) 29(1) 
C6A 6956(2) 10997(5) 2040(1) 27(1) 
C7A 7392(2) 10297(6) 2622(1) 28(1) 
C8A 7223(2) 11339(6) 3172(1) 31(1) 
C9A 7602(2) 10598(6) 3720(1) 31(1) 
C10A 8173(2) 8787(6) 3746(2) 37(1) 
C11A 8365(2) 7780(6) 3216(1) 34(1) 
C12A 7986(2) 8505(5) 2643(1) 29(1) 
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C13A 8178(2) 7423(5) 2086(1) 28(1) 
C14A 7727(2) 8035(5) 1545(1) 27(1) 
C15A 7865(2) 6827(5) 972(1) 28(1) 
C16A 8638(2) 4107(6) 462(1) 35(1) 
C17A 9178(2) 2054(6) 501(2) 41(1) 
C18A 10105(3) 2218(7) 917(2) 46(1) 
C19A 9815(3) 3001(7) 1537(2) 40(1) 
C20A 9237(2) 5029(5) 1488(1) 34(1) 
C21A 8885(2) 5627(6) 2107(1) 33(1) 
C22A 5837(2) 12114(6) -171(1) 35(1) 
C23A 5235(2) 16425(6) 1869(1) 34(1) 
C24A 6864(2) 13307(7) 4270(2) 39(1) 
O1B 4341(2) 2045(4) 4630(1) 32(1) 
O2B 4714(2) 110(4) 3655(1) 32(1) 
O3B 2634(2) 3803(4) 746(1) 37(1) 
N1B 1213(2) 9582(4) 4018(1) 26(1) 
C1B 2962(2) 5401(5) 3508(1) 23(1) 
C2B 3382(2) 4671(5) 4072(1) 24(1) 
C3B 3949(2) 2921(5) 4106(1) 25(1) 
C4B 4149(2) 1826(5) 3569(1) 26(1) 
C5B 3767(2) 2539(5) 3019(1) 25(1) 
C6B 3161(2) 4319(5) 2971(1) 24(1) 
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C7B 2732(2) 5039(5) 2394(1) 24(1) 
C8B 2893(2) 3986(6) 1843(1) 29(1) 
C9B 2510(2) 4726(6) 1295(1) 31(1) 
C10B 1945(2) 6542(6) 1277(1) 35(1) 
C11B 1762(2) 7547(6) 1802(1) 34(1) 
C12B 2140(2) 6843(5) 2377(1) 28(1) 
C13B 1933(2) 7902(5) 2934(1) 27(1) 
C14B 2319(2) 7197(5) 3478(1) 25(1) 
C15B 2100(2) 8283(5) 4062(1) 26(1) 
C16B 1180(2) 10734(6) 4588(1) 31(1) 
C17B 260(2) 12103(5) 4595(1) 35(1) 
C18B 267(3) 13627(6) 4069(2) 41(1) 
C19B 371(2) 12474(6) 3475(2) 37(1) 
C20B 1261(2) 10991(5) 3498(1) 28(1) 
C21B 1266(2) 9772(5) 2910(1) 32(1) 
C22B 4151(2) 3026(6) 5192(1) 35(1) 
C23B 4875(2) -1120(6) 3134(1) 32(1) 
C24B 3227(3) 1984(7) 743(2) 41(1) 
_____________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for 09047b. 
_____________________________________________________ 
O(1A)-C(3A) 1.364(4) 
O(1A)-C(22A) 1.426(4) 
O(2A)-C(4A) 1.371(4) 
O(2A)-C(23A) 1.422(4) 
O(3A)-C(9A) 1.371(4) 
O(3A)-C(24A) 1.429(5) 
N(1A)-C(20A) 1.461(4) 
N(1A)-C(15A) 1.465(4) 
N(1A)-C(16A) 1.469(4) 
C(1A)-C(6A) 1.411(4) 
C(1A)-C(2A) 1.422(4) 
C(1A)-C(14A) 1.439(5) 
C(2A)-C(3A) 1.363(5) 
C(2A)-H(2AA) 0.9500 
C(3A)-C(4A) 1.424(4) 
C(4A)-C(5A) 1.365(4) 
C(5A)-C(6A) 1.421(5) 
C(5A)-H(5AA) 0.9500 
C(6A)-C(7A) 1.455(4) 
C(7A)-C(12A) 1.412(5) 
C(7A)-C(8A) 1.417(4) 
C(8A)-C(9A) 1.373(4) 
C(8A)-H(8AA) 0.9500 
C(9A)-C(10A) 1.406(5) 
C(10A)-C(11A) 1.375(5) 
C(10A)-H(10A) 0.9500 
C(11A)-C(12A) 1.417(4) 
C(11A)-H(11A) 0.9500 
C(12A)-C(13A) 1.450(4) 
C(13A)-C(14A) 1.367(4) 
C(13A)-C(21A) 1.505(5) 
C(14A)-C(15A) 1.507(4) 
C(15A)-H(15A) 0.9900 
C(15A)-H(15B) 0.9900 
C(16A)-C(17A) 1.521(5) 
C(16A)-H(16A) 0.9900 
C(16A)-H(16B) 0.9900 
C(17A)-C(18A) 1.506(5) 
C(17A)-H(17A) 0.9900 
C(17A)-H(17B) 0.9900 
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C(18A)-C(19A) 1.527(5) 
C(18A)-H(18A) 0.9900 
C(18A)-H(18B) 0.9900 
C(19A)-C(20A) 1.532(5) 
C(19A)-H(19A) 0.9900 
C(19A)-H(19B) 0.9900 
C(20A)-C(21A) 1.515(4) 
C(20A)-H(20A) 1.0000 
C(21A)-H(21A) 0.9900 
C(21A)-H(21B) 0.9900 
C(22A)-H(22D) 0.9800 
C(22A)-H(22E) 0.9800 
C(22A)-H(22F) 0.9800 
C(23A)-H(23D) 0.9800 
C(23A)-H(23E) 0.9800 
C(23A)-H(23F) 0.9800 
C(24A)-H(24D) 0.9800 
C(24A)-H(24E) 0.9800 
C(24A)-H(24F) 0.9800 
O(1B)-C(3B) 1.367(3) 
O(1B)-C(22B) 1.429(4) 
O(2B)-C(4B) 1.358(4) 
O(2B)-C(23B) 1.426(4) 
O(3B)-C(9B) 1.369(4) 
O(3B)-C(24B) 1.427(5) 
N(1B)-C(15B) 1.457(4) 
N(1B)-C(16B) 1.465(4) 
N(1B)-C(20B) 1.474(4) 
C(1B)-C(6B) 1.415(4) 
C(1B)-C(2B) 1.419(4) 
C(1B)-C(14B) 1.453(4) 
C(2B)-C(3B) 1.370(5) 
C(2B)-H(2BA) 0.9500 
C(3B)-C(4B) 1.419(4) 
C(4B)-C(5B) 1.371(4) 
C(5B)-C(6B) 1.417(4) 
C(5B)-H(5BA) 0.9500 
C(6B)-C(7B) 1.446(4) 
C(7B)-C(12B) 1.417(5) 
C(7B)-C(8B) 1.421(4) 
C(8B)-C(9B) 1.374(4) 
C(8B)-H(8BA) 0.9500 
C(9B)-C(10B) 1.404(5) 
C(10B)-C(11B) 1.363(5) 
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C(10B)-H(10B) 0.9500 
C(11B)-C(12B) 1.416(4) 
C(11B)-H(11B) 0.9500 
C(12B)-C(13B) 1.447(4) 
C(13B)-C(14B) 1.360(4) 
C(13B)-C(21B) 1.510(5) 
C(14B)-C(15B) 1.512(4) 
C(15B)-H(15C) 0.9900 
C(15B)-H(15D) 0.9900 
C(16B)-C(17B) 1.521(4) 
C(16B)-H(16C) 0.9900 
C(16B)-H(16D) 0.9900 
C(17B)-C(18B) 1.528(5) 
C(17B)-H(17C) 0.9900 
C(17B)-H(17D) 0.9900 
C(18B)-C(19B) 1.522(5) 
C(18B)-H(18C) 0.9900 
C(18B)-H(18D) 0.9900 
C(19B)-C(20B) 1.532(4) 
C(19B)-H(19C) 0.9900 
C(19B)-H(19D) 0.9900 
C(20B)-C(21B) 1.521(4) 
C(20B)-H(20B) 1.0000 
C(21B)-H(21C) 0.9900 
C(21B)-H(21D) 0.9900 
C(22B)-H(22A) 0.9800 
C(22B)-H(22B) 0.9800 
C(22B)-H(22C) 0.9800 
C(23B)-H(23A) 0.9800 
C(23B)-H(23B) 0.9800 
C(23B)-H(23C) 0.9800 
C(24B)-H(24A) 0.9800 
C(24B)-H(24B) 0.9800 
C(24B)-H(24C) 0.9800 
 
C(3A)-O(1A)-C(22A) 117.9(3) 
C(4A)-O(2A)-C(23A) 116.7(2) 
C(9A)-O(3A)-C(24A) 116.7(3) 
C(20A)-N(1A)-C(15A) 111.1(2) 
C(20A)-N(1A)-C(16A) 112.4(2) 
C(15A)-N(1A)-C(16A) 107.6(2) 
C(6A)-C(1A)-C(2A) 118.6(3) 
C(6A)-C(1A)-C(14A) 120.1(3) 
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C(2A)-C(1A)-C(14A) 121.3(3) 
C(3A)-C(2A)-C(1A) 121.6(3) 
C(3A)-C(2A)-H(2AA) 119.2 
C(1A)-C(2A)-H(2AA) 119.2 
C(2A)-C(3A)-O(1A) 126.2(3) 
C(2A)-C(3A)-C(4A) 119.8(3) 
O(1A)-C(3A)-C(4A) 114.1(3) 
C(5A)-C(4A)-O(2A) 125.6(3) 
C(5A)-C(4A)-C(3A) 119.6(3) 
O(2A)-C(4A)-C(3A) 114.8(3) 
C(4A)-C(5A)-C(6A) 121.5(3) 
C(4A)-C(5A)-H(5AA) 119.2 
C(6A)-C(5A)-H(5AA) 119.2 
C(1A)-C(6A)-C(5A) 118.8(3) 
C(1A)-C(6A)-C(7A) 119.5(3) 
C(5A)-C(6A)-C(7A) 121.7(3) 
C(12A)-C(7A)-C(8A) 119.0(3) 
C(12A)-C(7A)-C(6A) 119.1(3) 
C(8A)-C(7A)-C(6A) 121.9(3) 
C(9A)-C(8A)-C(7A) 121.0(3) 
C(9A)-C(8A)-H(8AA) 119.5 
C(7A)-C(8A)-H(8AA) 119.5 
O(3A)-C(9A)-C(8A) 124.8(3) 
O(3A)-C(9A)-C(10A) 114.9(3) 
C(8A)-C(9A)-C(10A) 120.3(3) 
C(11A)-C(10A)-C(9A) 119.5(3) 
C(11A)-C(10A)-H(10A) 120.2 
C(9A)-C(10A)-H(10A) 120.2 
C(10A)-C(11A)-C(12A) 121.5(3) 
C(10A)-C(11A)-H(11A) 119.2 
C(12A)-C(11A)-H(11A) 119.2 
C(7A)-C(12A)-C(11A) 118.6(3) 
C(7A)-C(12A)-C(13A) 120.0(3) 
C(11A)-C(12A)-C(13A) 121.4(3) 
C(14A)-C(13A)-C(12A) 120.4(3) 
C(14A)-C(13A)-C(21A) 120.1(3) 
C(12A)-C(13A)-C(21A) 119.5(3) 
C(13A)-C(14A)-C(1A) 120.7(3) 
C(13A)-C(14A)-C(15A) 120.7(3) 
C(1A)-C(14A)-C(15A) 118.6(3) 
N(1A)-C(15A)-C(14A) 115.1(3) 
N(1A)-C(15A)-H(15A) 108.5 
C(14A)-C(15A)-H(15A) 108.5 
N(1A)-C(15A)-H(15B) 108.5 
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C(14A)-C(15A)-H(15B) 108.5 
H(15A)-C(15A)-H(15B) 107.5 
N(1A)-C(16A)-C(17A) 112.2(3) 
N(1A)-C(16A)-H(16A) 109.2 
C(17A)-C(16A)-H(16A) 109.2 
N(1A)-C(16A)-H(16B) 109.2 
C(17A)-C(16A)-H(16B) 109.2 
H(16A)-C(16A)-H(16B) 107.9 
C(18A)-C(17A)-C(16A) 110.2(3) 
C(18A)-C(17A)-H(17A) 109.6 
C(16A)-C(17A)-H(17A) 109.6 
C(18A)-C(17A)-H(17B) 109.6 
C(16A)-C(17A)-H(17B) 109.6 
H(17A)-C(17A)-H(17B) 108.1 
C(17A)-C(18A)-C(19A) 109.2(3) 
C(17A)-C(18A)-H(18A) 109.8 
C(19A)-C(18A)-H(18A) 109.8 
C(17A)-C(18A)-H(18B) 109.8 
C(19A)-C(18A)-H(18B) 109.8 
H(18A)-C(18A)-H(18B) 108.3 
C(18A)-C(19A)-C(20A) 112.2(3) 
C(18A)-C(19A)-H(19A) 109.2 
C(20A)-C(19A)-H(19A) 109.2 
C(18A)-C(19A)-H(19B) 109.2 
C(20A)-C(19A)-H(19B) 109.2 
H(19A)-C(19A)-H(19B) 107.9 
N(1A)-C(20A)-C(21A) 109.0(2) 
N(1A)-C(20A)-C(19A) 110.8(3) 
C(21A)-C(20A)-C(19A) 109.8(3) 
N(1A)-C(20A)-H(20A) 109.1 
C(21A)-C(20A)-H(20A) 109.1 
C(19A)-C(20A)-H(20A) 109.1 
C(13A)-C(21A)-C(20A) 113.5(3) 
C(13A)-C(21A)-H(21A) 108.9 
C(20A)-C(21A)-H(21A) 108.9 
C(13A)-C(21A)-H(21B) 108.9 
C(20A)-C(21A)-H(21B) 108.9 
H(21A)-C(21A)-H(21B) 107.7 
O(1A)-C(22A)-H(22D) 109.5 
O(1A)-C(22A)-H(22E) 109.5 
H(22D)-C(22A)-H(22E) 109.5 
O(1A)-C(22A)-H(22F) 109.5 
H(22D)-C(22A)-H(22F) 109.5 
H(22E)-C(22A)-H(22F) 109.5 
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O(2A)-C(23A)-H(23D) 109.5 
O(2A)-C(23A)-H(23E) 109.5 
H(23D)-C(23A)-H(23E) 109.5 
O(2A)-C(23A)-H(23F) 109.5 
H(23D)-C(23A)-H(23F) 109.5 
H(23E)-C(23A)-H(23F) 109.5 
O(3A)-C(24A)-H(24D) 109.5 
O(3A)-C(24A)-H(24E) 109.5 
H(24D)-C(24A)-H(24E) 109.5 
O(3A)-C(24A)-H(24F) 109.5 
H(24D)-C(24A)-H(24F) 109.5 
H(24E)-C(24A)-H(24F) 109.5 
C(3B)-O(1B)-C(22B) 117.9(3) 
C(4B)-O(2B)-C(23B) 117.3(2) 
C(9B)-O(3B)-C(24B) 117.6(3) 
C(15B)-N(1B)-C(16B) 107.6(2) 
C(15B)-N(1B)-C(20B) 110.2(2) 
C(16B)-N(1B)-C(20B) 110.6(2) 
C(6B)-C(1B)-C(2B) 118.8(3) 
C(6B)-C(1B)-C(14B) 120.0(3) 
C(2B)-C(1B)-C(14B) 121.2(3) 
C(3B)-C(2B)-C(1B) 121.3(3) 
C(3B)-C(2B)-H(2BA) 119.4 
C(1B)-C(2B)-H(2BA) 119.4 
O(1B)-C(3B)-C(2B) 125.4(3) 
O(1B)-C(3B)-C(4B) 114.4(3) 
C(2B)-C(3B)-C(4B) 120.2(3) 
O(2B)-C(4B)-C(5B) 125.6(3) 
O(2B)-C(4B)-C(3B) 115.2(3) 
C(5B)-C(4B)-C(3B) 119.2(3) 
C(4B)-C(5B)-C(6B) 121.9(3) 
C(4B)-C(5B)-H(5BA) 119.0 
C(6B)-C(5B)-H(5BA) 119.0 
C(1B)-C(6B)-C(5B) 118.6(3) 
C(1B)-C(6B)-C(7B) 119.4(3) 
C(5B)-C(6B)-C(7B) 122.0(3) 
C(12B)-C(7B)-C(8B) 119.3(3) 
C(12B)-C(7B)-C(6B) 119.2(3) 
C(8B)-C(7B)-C(6B) 121.6(3) 
C(9B)-C(8B)-C(7B) 121.0(3) 
C(9B)-C(8B)-H(8BA) 119.5 
C(7B)-C(8B)-H(8BA) 119.5 
O(3B)-C(9B)-C(8B) 124.4(3) 
O(3B)-C(9B)-C(10B) 115.8(3) 
 106 
C(8B)-C(9B)-C(10B) 119.7(3) 
C(11B)-C(10B)-C(9B) 120.1(3) 
C(11B)-C(10B)-H(10B) 119.9 
C(9B)-C(10B)-H(10B) 119.9 
C(10B)-C(11B)-C(12B) 122.2(3) 
C(10B)-C(11B)-H(11B) 118.9 
C(12B)-C(11B)-H(11B) 118.9 
C(11B)-C(12B)-C(7B) 117.7(3) 
C(11B)-C(12B)-C(13B) 122.0(3) 
C(7B)-C(12B)-C(13B) 120.4(3) 
C(14B)-C(13B)-C(12B) 120.3(3) 
C(14B)-C(13B)-C(21B) 120.0(3) 
C(12B)-C(13B)-C(21B) 119.6(3) 
C(13B)-C(14B)-C(1B) 120.7(3) 
C(13B)-C(14B)-C(15B) 120.7(3) 
C(1B)-C(14B)-C(15B) 118.6(3) 
N(1B)-C(15B)-C(14B) 114.2(2) 
N(1B)-C(15B)-H(15C) 108.7 
C(14B)-C(15B)-H(15C) 108.7 
N(1B)-C(15B)-H(15D) 108.7 
C(14B)-C(15B)-H(15D) 108.7 
H(15C)-C(15B)-H(15D) 107.6 
N(1B)-C(16B)-C(17B) 111.7(2) 
N(1B)-C(16B)-H(16C) 109.3 
C(17B)-C(16B)-H(16C) 109.3 
N(1B)-C(16B)-H(16D) 109.3 
C(17B)-C(16B)-H(16D) 109.3 
H(16C)-C(16B)-H(16D) 107.9 
C(16B)-C(17B)-C(18B) 109.6(2) 
C(16B)-C(17B)-H(17C) 109.7 
C(18B)-C(17B)-H(17C) 109.7 
C(16B)-C(17B)-H(17D) 109.7 
C(18B)-C(17B)-H(17D) 109.7 
H(17C)-C(17B)-H(17D) 108.2 
C(19B)-C(18B)-C(17B) 109.6(3) 
C(19B)-C(18B)-H(18C) 109.7 
C(17B)-C(18B)-H(18C) 109.7 
C(19B)-C(18B)-H(18D) 109.7 
C(17B)-C(18B)-H(18D) 109.7 
H(18C)-C(18B)-H(18D) 108.2 
C(18B)-C(19B)-C(20B) 112.9(3) 
C(18B)-C(19B)-H(19C) 109.0 
C(20B)-C(19B)-H(19C) 109.0 
C(18B)-C(19B)-H(19D) 109.0 
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C(20B)-C(19B)-H(19D) 109.0 
H(19C)-C(19B)-H(19D) 107.8 
N(1B)-C(20B)-C(21B) 109.9(3) 
N(1B)-C(20B)-C(19B) 110.7(2) 
C(21B)-C(20B)-C(19B) 109.9(3) 
N(1B)-C(20B)-H(20B) 108.8 
C(21B)-C(20B)-H(20B) 108.8 
C(19B)-C(20B)-H(20B) 108.8 
C(13B)-C(21B)-C(20B) 114.9(3) 
C(13B)-C(21B)-H(21C) 108.5 
C(20B)-C(21B)-H(21C) 108.5 
C(13B)-C(21B)-H(21D) 108.5 
C(20B)-C(21B)-H(21D) 108.5 
H(21C)-C(21B)-H(21D) 107.5 
O(1B)-C(22B)-H(22A) 109.5 
O(1B)-C(22B)-H(22B) 109.5 
H(22A)-C(22B)-H(22B) 109.5 
O(1B)-C(22B)-H(22C) 109.5 
H(22A)-C(22B)-H(22C) 109.5 
H(22B)-C(22B)-H(22C) 109.5 
O(2B)-C(23B)-H(23A) 109.5 
O(2B)-C(23B)-H(23B) 109.5 
H(23A)-C(23B)-H(23B) 109.5 
O(2B)-C(23B)-H(23C) 109.5 
H(23A)-C(23B)-H(23C) 109.5 
H(23B)-C(23B)-H(23C) 109.5 
O(3B)-C(24B)-H(24A) 109.5 
O(3B)-C(24B)-H(24B) 109.5 
H(24A)-C(24B)-H(24B) 109.5 
O(3B)-C(24B)-H(24C) 109.5 
H(24A)-C(24B)-H(24C) 109.5 
H(24B)-C(24B)-H(24C) 109.5 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for 09047b.  The 
anisotropic 
displacement factor exponent takes the form: -2p2[ h2a*2U11 + ... + 2 h k a* b* U12 
] 
_____________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_____________________________________________________________________ 
O1A 43(1)  34(1) 26(1)  -4(1) 0(1)  12(1) 
O2A 43(1)  34(1) 27(1)  -3(1) 2(1)  14(1) 
O3A 49(1)  42(2) 22(1)  -3(1) 0(1)  0(1) 
N1A 36(1)  27(1) 32(1)  -2(1) 2(1)  3(1) 
C1A 26(1)  25(2) 27(2)  0(2) 5(1)  -3(1) 
C2A 30(2)  25(2) 25(2)  -5(2) 5(1)  -1(1) 
C3A 27(1)  30(2) 25(2)  0(2) 2(1)  -1(1) 
C4A 27(2)  24(2) 31(2)  -4(2) 4(1)  2(1) 
C5A 31(2)  31(2) 25(2)  -2(2) 7(1)  -2(2) 
C6A 23(1)  25(2) 33(2)  -2(1) 6(1)  -5(1) 
C7A 26(1)  31(2) 25(2)  0(2) 2(1)  -5(1) 
C8A 32(2)  28(2) 32(2)  -2(2) 5(1)  -5(2) 
C9A 31(2)  38(2) 23(2)  -1(2) 2(1)  -8(2) 
C10A 43(2)  38(2) 29(2)  4(2) -4(1)  -2(2) 
C11A 39(2)  33(2) 31(2)  3(2) -2(1)  2(2) 
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C12A 30(2)  28(2) 30(2)  2(2) 4(1)  -5(2) 
C13A 28(2)  29(2) 28(2)  0(2) 0(1)  -4(1) 
C14A 25(1)  28(2) 28(2)  0(2) 6(1)  -4(1) 
C15A 30(2)  25(2) 30(2)  -1(2) 1(1)  2(1) 
C16A 36(2)  34(2) 34(2)  -5(2) 1(1)  6(2) 
C17A 41(2)  36(2) 45(2)  -8(2) 5(2)  7(2) 
C18A 45(2)  47(2) 47(2)  -3(2) 3(2)  15(2) 
C19A 41(2)  40(2) 38(2)  1(2) 0(1)  9(2) 
C20A 33(2)  34(2) 36(2)  0(2) 1(1)  2(2) 
C21A 36(2)  33(2) 28(2)  1(2) -1(1)  5(2) 
C22A 47(2)  30(2) 27(2)  -4(2) -1(1)  1(2) 
C23A 37(2)  33(2) 33(2)  -4(2) 7(1)  7(2) 
C24A 45(2)  44(2) 28(2)  -7(2) 2(1)  1(2) 
O1B 40(1)  36(1) 18(1)  -1(1) -2(1)  9(1) 
O2B 41(1)  33(1) 23(1)  -3(1) 1(1)  11(1) 
O3B 46(1)  43(2) 23(1)  -1(1) 0(1)  -3(1) 
N1B 28(1)  19(1) 30(1)  2(1) 3(1)  -1(1) 
C1B 24(1)  22(2) 24(2)  1(1) 1(1)  -6(1) 
C2B 27(1)  24(2) 22(2)  -2(1) 0(1)  -2(1) 
C3B 26(1)  26(2) 21(2)  -1(2) 0(1)  -2(1) 
C4B 26(1)  25(2) 26(2)  1(2) 2(1)  2(1) 
C5B 28(1)  29(2) 19(2)  -2(1) 3(1)  -1(1) 
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C6B 24(1)  24(2) 23(2)  3(1) 0(1)  -4(1) 
C7B 26(1)  24(2) 23(2)  1(1) 3(1)  -7(1) 
C8B 29(2)  30(2) 26(2)  2(2) 2(1)  -4(1) 
C9B 33(2)  36(2) 23(2)  1(2) 1(1)  -9(2) 
C10B 36(2)  44(2) 24(2)  11(2) -4(1)  -2(2) 
C11B 33(2)  35(2) 33(2)  5(2) -1(1)  1(2) 
C12B 28(1)  29(2) 26(2)  4(2) -1(1)  -8(1) 
C13B 28(2)  21(2) 32(2)  3(2) 3(1)  -5(1) 
C14B 26(1)  20(2) 29(2)  2(2) 1(1)  -3(1) 
C15B 31(2)  23(2) 26(2)  2(1) 4(1)  -1(1) 
C16B 31(2)  31(2) 32(2)  -1(1) 5(1)  -1(1) 
C17B 38(2)  31(2) 36(2)  -3(2) 6(1)  3(2) 
C18B 45(2)  31(2) 48(2)  0(2) 8(2)  12(2) 
C19B 40(2)  31(2) 40(2)  8(2) 4(1)  8(2) 
C20B 29(2)  23(2) 33(2)  3(1) 3(1)  -3(1) 
C21B 35(2)  26(2) 35(2)  6(2) 1(1)  1(2) 
C22B 46(2)  36(2) 21(2)  -2(2) -2(1)  4(2) 
C23B 39(2)  30(2) 26(2)  -7(2) 4(1)  6(2) 
C24B 56(2)  43(2) 24(2)  -6(2) 2(2)  -3(2) 
_____________________________________________________________________
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Table 5.   Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 
103) 
for 09047b. 
_____________________________________________________________________ 
 x  y  z  U(eq) 
_____________________________________________________________________ 
 
H2AA 6760 9769 590 32 
H5AA 6245 13570 2346 34 
H8AA 6842 12569 3161 37 
H10A 8425 8264 4126 44 
H11A 8761 6570 3235 41 
H15A 7198 6586 768 34 
H15B 8256 7670 696 34 
H16A 9074 5132 276 42 
H16B 8023 3964 195 42 
H17A 8727 996 657 49 
H17B 9365 1632 90 49 
H18A 10587 3175 741 55 
H18B 10429 857 962 55 
H19A 10429 3198 1801 48 
H19B 9397 1957 1729 48 
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H20A 9690 6124 1343 41 
H21A 8548 4434 2284 39 
H21B 9476 5968 2377 39 
H22D 5499 12880 -505 52 
H22E 5536 10748 -145 52 
H22F 6549 11978 -246 52 
H23D 4835 17630 1747 52 
H23E 5879 16871 2057 52 
H23F 4876 15614 2162 52 
H24D 6818 13805 4687 59 
H24E 6193 12980 4098 59 
H24F 7165 14370 4023 59 
H2BA 3268 5410 4434 29 
H5BA 3912 1817 2660 30 
H8BA 3270 2751 1853 34 
H10B 1690 7071 898 42 
H11B 1368 8759 1781 40 
H15C 2014 7242 4383 32 
H15D 2685 9138 4191 32 
H16C 1790 11590 4642 37 
H16D 1175 9760 4933 37 
H17C 259 12855 4986 42 
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H17D -353 11253 4557 42 
H18C -363 14428 4048 50 
H18D 833 14594 4135 50 
H19C 452 13477 3144 44 
H19D -252 11692 3378 44 
H20B 1894 11804 3544 34 
H21C 573 9330 2798 38 
H21D 1483 10688 2583 38 
H22A 4472 2245 5529 52 
H22B 3428 3084 5241 52 
H22C 4423 4421 5193 52 
H23A 5281 -2318 3256 47 
H23B 5226 -312 2837 47 
H23C 4229 -1577 2952 47 
H24A 3278 1509 324 62 
H24B 2912 917 981 62 
H24C 3898 2278 922 62 
_____________________________________________________________________
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Table 6.  Torsion angles [°] for 09047b. 
_____________________________________________________________________
C6A-C1A-C2A-C3A 2.0(4) 
C14A-C1A-C2A-C3A -176.7(3) 
C1A-C2A-C3A-O1A 176.5(3) 
C1A-C2A-C3A-C4A -3.0(4) 
C22A-O1A-C3A-C2A 2.5(4) 
C22A-O1A-C3A-C4A -178.0(3) 
C23A-O2A-C4A-C5A 0.5(4) 
C23A-O2A-C4A-C3A -178.3(3) 
C2A-C3A-C4A-C5A 1.9(5) 
O1A-C3A-C4A-C5A -177.6(3) 
C2A-C3A-C4A-O2A -179.3(3) 
O1A-C3A-C4A-O2A 1.2(4) 
O2A-C4A-C5A-C6A -178.6(3) 
C3A-C4A-C5A-C6A 0.1(5) 
C2A-C1A-C6A-C5A 0.1(4) 
C14A-C1A-C6A-C5A 178.7(3) 
C2A-C1A-C6A-C7A 179.6(3) 
C14A-C1A-C6A-C7A -1.8(4) 
C4A-C5A-C6A-C1A -1.1(4) 
C4A-C5A-C6A-C7A 179.4(3) 
C1A-C6A-C7A-C12A 1.4(4) 
C5A-C6A-C7A-C12A -179.1(3) 
C1A-C6A-C7A-C8A -177.3(3) 
C5A-C6A-C7A-C8A 2.2(5) 
C12A-C7A-C8A-C9A -1.9(5) 
C6A-C7A-C8A-C9A 176.8(3) 
C24A-O3A-C9A-C8A 2.6(5) 
C24A-O3A-C9A-C10A -177.7(3) 
C7A-C8A-C9A-O3A -179.9(3) 
C7A-C8A-C9A-C10A 0.4(5) 
O3A-C9A-C10A-C11A -178.7(3) 
C8A-C9A-C10A-C11A 1.0(5) 
C9A-C10A-C11A-C12A -1.0(5) 
C8A-C7A-C12A-C11A 1.9(4) 
C6A-C7A-C12A-C11A -176.8(3) 
C8A-C7A-C12A-C13A -179.4(3) 
C6A-C7A-C12A-C13A 1.8(4) 
C10A-C11A-C12A-C7A -0.5(5) 
C10A-C11A-C12A-C13A-179.1(3) 
C7A-C12A-C13A-C14A -4.9(5) 
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C11A-C12A-C13A-C14A173.7(3) 
C7A-C12A-C13A-C21A 174.5(3) 
C11A-C12A-C13A-C21A -6.8(5) 
C12A-C13A-C14A-C1A 4.6(5) 
C21A-C13A-C14A-C1A -174.8(3) 
C12A-C13A-C14A-C15A-175.6(3) 
C21A-C13A-C14A-C15A 5.0(5) 
C6A-C1A-C14A-C13A -1.3(4) 
C2A-C1A-C14A-C13A 177.3(3) 
C6A-C1A-C14A-C15A 178.9(3) 
C2A-C1A-C14A-C15A -2.5(4) 
C20A-N1A-C15A-C14A -44.2(3) 
C16A-N1A-C15A-C14A -167.5(3) 
C13A-C14A-C15A-N1A 9.1(4) 
C1A-C14A-C15A-N1A -171.1(2) 
C20A-N1A-C16A-C17A 56.9(4) 
C15A-N1A-C16A-C17A 179.4(3) 
N1A-C16A-C17A-C18A -57.5(4) 
C16A-C17A-C18A-C19A55.7(4) 
C17A-C18A-C19A-C20A-55.1(4) 
C15A-N1A-C20A-C21A 64.1(3) 
C16A-N1A-C20A-C21A -175.4(3) 
C15A-N1A-C20A-C19A -174.9(3) 
C16A-N1A-C20A-C19A -54.4(4) 
C18A-C19A-C20A-N1A 54.2(4) 
C18A-C19A-C20A-C21A174.7(3) 
C14A-C13A-C21A-C20A15.6(4) 
C12A-C13A-C21A-C20A-163.9(3) 
N1A-C20A-C21A-C13A -49.5(4) 
C19A-C20A-C21A-C13A-171.1(3) 
C6B-C1B-C2B-C3B -1.8(4) 
C14B-C1B-C2B-C3B 176.8(3) 
C22B-O1B-C3B-C2B -0.3(4) 
C22B-O1B-C3B-C4B -178.4(3) 
C1B-C2B-C3B-O1B -176.5(3) 
C1B-C2B-C3B-C4B 1.6(4) 
C23B-O2B-C4B-C5B -3.8(4) 
C23B-O2B-C4B-C3B 175.6(3) 
O1B-C3B-C4B-O2B -1.4(4) 
C2B-C3B-C4B-O2B -179.7(3) 
O1B-C3B-C4B-C5B 178.1(3) 
C2B-C3B-C4B-C5B -0.1(4) 
O2B-C4B-C5B-C6B 178.3(3) 
C3B-C4B-C5B-C6B -1.2(4) 
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C2B-C1B-C6B-C5B 0.5(4) 
C14B-C1B-C6B-C5B -178.1(3) 
C2B-C1B-C6B-C7B 179.6(3) 
C14B-C1B-C6B-C7B 1.0(4) 
C4B-C5B-C6B-C1B 1.0(4) 
C4B-C5B-C6B-C7B -178.1(3) 
C1B-C6B-C7B-C12B 1.5(4) 
C5B-C6B-C7B-C12B -179.4(3) 
C1B-C6B-C7B-C8B -178.8(3) 
C5B-C6B-C7B-C8B 0.3(4) 
C12B-C7B-C8B-C9B 2.1(4) 
C6B-C7B-C8B-C9B -177.6(3) 
C24B-O3B-C9B-C8B -2.0(4) 
C24B-O3B-C9B-C10B 178.3(3) 
C7B-C8B-C9B-O3B 179.9(3) 
C7B-C8B-C9B-C10B -0.5(5) 
O3B-C9B-C10B-C11B 178.5(3) 
C8B-C9B-C10B-C11B -1.1(5) 
C9B-C10B-C11B-C12B 1.1(5) 
C10B-C11B-C12B-C7B 0.4(5) 
C10B-C11B-C12B-C13B-179.2(3) 
C8B-C7B-C12B-C11B -2.0(4) 
C6B-C7B-C12B-C11B 177.7(3) 
C8B-C7B-C12B-C13B 177.7(3) 
C6B-C7B-C12B-C13B -2.6(4) 
C11B-C12B-C13B-C14B-179.2(3) 
C7B-C12B-C13B-C14B 1.2(4) 
C11B-C12B-C13B-C21B 2.2(4) 
C7B-C12B-C13B-C21B -177.5(3) 
C12B-C13B-C14B-C1B 1.4(4) 
C21B-C13B-C14B-C1B -180.0(3) 
C12B-C13B-C14B-C15B-179.5(3) 
C21B-C13B-C14B-C15B -0.9(4) 
C6B-C1B-C14B-C13B -2.5(4) 
C2B-C1B-C14B-C13B 178.9(3) 
C6B-C1B-C14B-C15B 178.4(3) 
C2B-C1B-C14B-C15B -0.2(4) 
C16B-N1B-C15B-C14B -172.3(3) 
C20B-N1B-C15B-C14B -51.7(3) 
C13B-C14B-C15B-N1B 20.6(4) 
C1B-C14B-C15B-N1B -160.3(3) 
C15B-N1B-C16B-C17B -178.4(3) 
C20B-N1B-C16B-C17B 61.2(3) 
N1B-C16B-C17B-C18B -59.5(4) 
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C16B-C17B-C18B-C19B 53.9(4) 
C17B-C18B-C19B-C20B -52.3(4) 
C15B-N1B-C20B-C21B 62.7(3) 
C16B-N1B-C20B-C21B -178.5(2) 
C15B-N1B-C20B-C19B -175.8(3) 
C16B-N1B-C20B-C19B -57.0(3) 
C18B-C19B-C20B-N1B 53.9(4) 
C18B-C19B-C20B-C21B175.4(3) 
C14B-C13B-C21B-C20B 12.6(4) 
C12B-C13B-C21B-C20B-168.8(3) 
N1B-C20B-C21B-C13B -43.0(3) 
C19B-C20B-C21B-C13B-165.0(3)
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4.2.2 Chapter 2 
General procedure of sequential, one-pot synthesis of flavones and chromones 
Step 1.  DIEA (2.5 mL, 14.3 mmol) was added to the appropriate salicylaldehyde 
derivative (4.8 mmol) in CH2Cl2 (10 mL) and stirred for 5 min at room temperature 
before MOM-Cl (0.5 mL, 6.2 mmol) was added to the reaction medium and the 
resulting reaction mixture was stirred overnight at this temperature.  The reaction was 
quenched with saturated aq. NaHCO3, transferred to a separatory funnel, and the 
layers were separated.  The aqueous phase was extracted twice more with CH2Cl2 and 
the combined organic layers were concentrated, and used without further purification.  
Step 2. To a stirred solution of the appropriate terminal alkyne (7.2 mmol) in THF 
(10 mL) at 0 ºC was added nBuLi (2.5 M in hexanes, 2.8 mL, 7.2 mmol) dropwise 
and warmed to room temperature after 30 min.  The generated lithiated alkyne was 
added to the crude aldehyde in THF (10 mL) at 0 ºC.  The flask containing the alkyne 
was washed with THF (5 mL) and transferred to the aldehyde containing flask.  The 
resulting reaction was monitored by TLC (EtOAc in hexanes) and after complete 
consumption of starting material (30-60 min) the reaction medium was transferred to 
a separatory funnel containing saturated aq. NH4Cl and EtOAc.  The layers were 
separated and the aqueous phase was extracted twice more with EtOAc.  The 
combined organic phases were  washed with brine, dried over Na2SO4, concentrated, 
and used without further purification.  
Step 3. The crude propargyl alcohol and MnO2 (2.1 g, 24 mmol) were combined in 
1,2-dichloroethane (40 mL) and refluxed overnight.  (Note: In most cases the 
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reactions demonstrated complete conversion by TLC analysis; however, electron-
deficient ynones required additional MnO2 and longer reaction times to drive the 
reaction to completion).  The reaction mixture was cooled to room temperature, 
filtered through a celite plug, and concentrated to afford the crude ynone that was 
used in the next reaction without purification.  
Step 4. Trifluoroacetic acid (2 mL) was added to the crude ynone in CH2Cl2 (18 mL) 
under an ambient atmosphere and stirred for 30 min at room temperature.  The 
reaction was concentrated to dryness and used immediately in the next step without 
purification.  
Step 5. The resulting crude ynone was dissolved in MeCN (480 mL) and K2CO3 (2.0 
g, 14.3 mmol) was added to the stirring solution and stirred at ambient atmosphere 
overnight. Silica gel (~45g) was added to the reaction and was  concentrated to 
dryness and purified by MPLC on silica gel (0-60% EtOAc in hexanes, 60 min, 254 
nm) to afford the corresponding flavones. 
OH
O
 
1-(2-Hydroxyphenyl)-3-phenylprop-2-yn-1-one (107). Steps 1-4 of the general 
procedure was used to afford 5.07 g of the title compound as a yellow solid (74%). 
The spectral data are consistent with those reported in the literature.104 1H NMR (400 
MHz, CDCl3) δ 6.98-7.02 (2H, m), 7.42-7.46 (2H, m), 7.50-7.55 (2H, m), 7.68-7.71 
(2H, m), 8.12-8.14 (1H, m), 11.76 (1H, s).  13C NMR (100 MHz, CDCl3) δ 85.79, 
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96.15, 118.25, 119.53, 119.78, 120.88, 128.89, 131.31, 133.14, 133.25, 137.28, 
162.91, 182.38. 
O
O
 
Flavone (108). The general procedure was used to afford 800 mg of the title 
compound as a white solid (77%). The spectral data are consistent with those reported 
in the literature.132 1H NMR (400 MHz, CDCl3) δ 6.80 (1H, s), 7.39 (1H, t, J = 7.52 
Hz), 7.47-7.55 (4H, m), 7.65-7.69 (1H, m), 7.88-7.90 (2H, m), 8.21 (1H, dd, J = 1.56, 
7.92 Hz).  13C NMR (100 MHz, CDCl3) δ 107.62, 118.14, 124.01, 125.27, 125.73, 
126.32, 129.09, 131.66, 131.80, 133.82, 156.29, 163.40, 178.45. 
O
O
OMe  
2-(4-Methoxyphenyl)-4H-chromen-4-one (110). The general procedure was used to 
afford 713 mg of the title compound as a yellow solid (59%). The spectral data are 
consistent with those reported in the literature.133 1H NMR (400 MHz, CDCl3) δ 3.89 
(3H, s), 6.75 (1H, s), 7.01 (1H, dd, J = 2.1, 5.0 Hz), 7.04 (1H, dd, J = 2.9, 5.0 Hz), 
7.39-7.43 (1H, m), 7.55 (1H, dd, J = 0.7, 8.4 Hz), 7.68 (1H, ddd, J = 1.7, 7.1, 8.6 
Hz), 7.87 (1H, dd, J = 2.1, 5.0 Hz), 7.90 (1H, dd, J = 2.9, 5.0 Hz), 8.22 (1H, dd, J = 
1.6, 7.9 Hz).  13C NMR (100 MHz, CDCl3) δ 55.65, 106.35, 114.61, 118.10, 124.10, 
124.40, 125.21, 125.81, 128.15, 133.69, 156.33, 162.55, 163.54, 178.51. 
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O
O
CF3  
2-(4-(Trifluoromethyl)phenyl)-4H-chromen-4-one (112). The general procedure 
was used to afford 752 mg of the title compound as a yellow solid (38%). 1H NMR 
(400 MHz, CDCl3) δ 6.83 (1H, s), 7.47 (1H, d, 8.9 Hz), 7.50-7.56 (3H, m), 7.77 (1H, 
dd, J = 2.5, 8.9 Hz), 7.89-7.92 (2H, m), 8.35 (1H, d, J = 2.4 Hz).  13C NMR (100 
MHz, CDCl3) δ 110.72, 113.08, 121.35, 123.97, 123.98 (1C, q, J = 272.2 Hz), 
124.93, 125.80 (1C, q, J = 3.7 Hz), 130.58, 130.90, 131.23, 131.50, 135.80 (1C, d, J 
= 1.2 Hz), 147.83, 166.34, 184.72. IR (neat, NaCl): 2924, 1645, 1470, 1325, 1117 
cm-1. MP = 137-139 ºC. HRMS (ESI+): m/z calc’d for C16H10F3O2, 291.0634; found 
291.0633. 
O
O
Me
 
2-o-Tolyl-4H-chromen-4-one (114). The general procedure was used to afford 518 
mg of the title compound as a yellow solid (44%). The spectral data are consistent 
with those reported in the literature.134 1H NMR (400 MHz, CDCl3) δ 2.48 (3H, s), 
6.49 (1H, s), 7.30-7.33 (2H, s), 7.39-7.45 (2H, m), 7.49 (1H, d, J = 8.2 Hz), 7.51-7.54 
(1H, m), 7.68 (1H, ddd, J = 1.7, 7.2, 8.6 Hz), 8.26 (1H, dd, J = 1.6, 7.9 Hz). 13C 
NMR (100 MHz, CDCl3) δ 20.64, 112.05, 118.14, 123.90, 125.33, 125.83, 126.30, 
129.29, 130.82, 131.36, 132.72, 133.86, 156.56, 166.16, 178.36. 
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O
O
S
 
2-(Thiophen-3-yl)-4H-chromen-4-one (116). The general procedure was used to 
afford 793 mg of the title compound as a tan solid (74%). 1H NMR (400 MHz, 
CDCl3) δ 6.64 (1H, s), 7.35-7.39 (1H, s), 7.42 (1H, dd, J = 3.0, 5.2 Hz), 7.45 (1H, dd, 
J = 1.32, 5.2 Hz), 7.48-7.50 (1H, m), 7.65 (1H, ddd, J = 1.7, 7.2, 8.6 Hz), 7.99 (1H, 
dd, J = 1.3, 3.0 Hz), 8.19 (1H, dd, J = 1.6, 7.9 Hz).  13C NMR (100 MHz, CDCl3) δ 
107.30, 118.08, 124.12, 125.17, 125.27, 125.80, 126.95, 127.50, 133.83, 134.34, 
156.18, 159.66, 178.54. IR (neat, NaCl): 3084, 1640, 1572, 1465, 1358, 1128 cm-1.  
MP = 113-115 °C. HRMS (ESI+): m/z calc’d for C13H8NaO2S, 251.0143; found 
251.0139. 
O
O
 
4H-Chromen-4-one (118). The general procedure was used to afford 405 mg of the 
title compound as a white solid (58%). The spectral data are consistent with those 
reported in the literature.132 1H NMR (400 MHz, CDCl3) δ 6.32 (1H, d, J = 6.0 Hz), 
7.36-7.40 (1H, m), 7.43 (1H, dd, J = 0.6, 8.6 Hz), 7.65 (1H, ddd, J = 1.7, 7.2, 8.6 
Hz), 7.83 (1H, d, J = 6.0 Hz), 8.18 (1H, dd, J = 1.62, 7.98 Hz).  13C NMR (100 MHz, 
CDCl3) δ 113.09, 118.27, 124.99, 125.33, 125.89, 133.85, 155.40, 156.60, 177.69. 
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O
O
 
2-Pentyl-4H-chromen-4-one (120). The general procedure was used to afford 918 
mg of the title compound as an oily solid  (91%). The spectral data are consistent with 
those reported in the literature.84 1H NMR (400 MHz, CDCl3) δ 0.90-0.93 (3H, m), 
1.34-1.41 (4H, m), 1.71-1.76 (2H, m), 2.61 (2H, t, J = 7.6 Hz), 6.17 (1H, s), 7.35-
7.39 (1H, m), 7.42 (1H, d, J = 8.44 Hz), 7.64 (1H, ddd, J = 1.7, 7.2, 8.6 Hz), 8.18 
(1H, dd, J = 1.58, 7.94 Hz).  13C NMR (100 MHz, CDCl3) δ 14.04, 22.47, 26.61, 
31.26, 34.34, 109.96, 117.98, 123.89, 125.01, 125.81, 133.52, 156.66, 169.96, 178.54. 
O
O
OH
 
2-(Hydroxymethyl)-4H-chromen-4-one (122). The general procedure was used to 
afford 630 mg of the title compound as a yellow solid (14%). The spectral data are 
consistent with those reported in the literature.135 1H NMR (400 MHz, d6-DMSO) δ 
4.49 (2H, dd, J = 0.8, 6.1 Hz), 5.84 (1H, t, J = 6.1 Hz), 6.38 (1H, s), 7.49-7.53 (1H, 
m), 7.64-7.66 (1H, m), 7.83 (1H, ddd, J = 1.7, 7.1, 8.6 Hz), 8.07 (1H, dd, J = 1.6, 8.0 
Hz).  13C NMR (100 MHz, d6-DMSO) δ 59.80, 107.27, 118.21, 123.43, 124.93, 
125.34, 134.18, 155.67, 169.78, 176.79. 
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O
O
OTBS  
2-((tert-Butyldimethylsilyloxy)methyl)-4H-chromen-4-one (123). The general 
procedure was used to afford 961 mg of the title compound as a tan solid (13%). 1H 
NMR (400 MHz, CDCl3) δ 0.14 (6H, s), 0.95 (9H, s), 4.58 (2H, d, 1.0 Hz), 6.47 (1H, 
t, 1.0 Hz), 7.35-7.40 (2H, m), 7.63 (1H, ddd, J = 1.7, 7.1, 10.1 Hz), 8.19 (1H, dd, J = 
1.4, 7.9 Hz).  13C NMR (100 MHz, CDCl3) δ -5.30, 18.44, 25.91, 61.79, 108.11, 
117.90, 124.27, 125.16, 125.98, 133.70, 156.23, 168.27, 178.41. IR (neat, NaCl): 
1639, 1596, 1466, 1355, 1095 cm-1.  MP = 159-161 °C. HRMS (ESI+): m/z calc’d for 
C16H23O3Si, 291.1416; found 291.1402. 
O
O
OH
MeO  
2-(Hydroxymethyl)-7-methoxy-4H-chromen-4-one (125). The general procedure 
was used to afford 68 mg of the title compound as a white solid (7%). The spectral 
data are consistent with those reported in the literature.136 1H NMR (400 MHz, d6-
DMSO) δ 3.92 (3H, s), 4.45 (2H, dd, J = 0.9, 6.1 Hz), 5.80 (1H, t, 6.1 Hz), 6.29 (1H, 
s), 7.08 (1H, dd, J = 2.42, 8.82 Hz), 7.14 (1H, d, J = 2.4 Hz), 7.96 (1H, d, J = 8.84 
Hz).  13C NMR (100 MHz, d6-DMSO) δ 56.06, 59.74, 100.69, 107.19, 114.41, 
117.17, 126.33, 157.48, 163.74, 169.11, 176.16. 
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2-(Methoxymethyl)-4H-chromen-4-one (127). The general procedure was used to 
afford 348 mg of the title compound as an oily solid (38%). 1H NMR (400 MHz, 
CDCl3) δ 3.49 (3H, s), 4.36 (2H, s), 6.40 (1H, s), 7.39 (1H, t, J = 7.5 Hz), 7.44 (1H, d, 
J = 8.4 Hz), 7.63-7.67 (1H, m), 8.18 (1H, d, J = 8.0 Hz).  13C NMR (100 MHz, 
CDCl3) δ 59.34, 70.87, 109.74, 118.10, 124.15, 125.30, 125.89, 133.86, 156.40, 
164.96, 178.21. IR (neat, NaCl): 2933, 1656, 1466, 1349, 1123, 758 cm-1.  HRMS 
(ESI+): m/z calc’d for C11H11O3, 191.0708; found 191.0706. 
O
O
Br
 
6-Bromo-2-phenyl-4H-chromen-4-one (129). The general procedure was used to 
afford 1.02 g of the title compound as a tan solid (72%). The spectral data are 
consistent with those reported in the literature.90 1H NMR (400 MHz, CDCl3) δ 7.26 
(1H, s), 7.48 (1H, d, J = 8.84 Hz), 7.52-7.57 (3H, m), 7.79 (1H, dd, J = 2.5, 8.8 Hz), 
7.91-7.93 (2H, m), 8.37 (1H, d, J = 2.4 Hz).  13C NMR (100 MHz, CDCl3) δ 107.62, 
118.77, 120.16, 125.35, 126.41, 128.45, 129.22, 131.43, 131.99, 136.82, 155.07, 
163.75, 177.10. 
 
 126 
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6-Methoxy-2-phenyl-4H-chromen-4-one (131). The general procedure was used to 
afford 601 mg of the title compound as a yellow solid (50%). The spectral data are 
consistent with those reported in the literature.137,138 1H NMR (400 MHz, CDCl3) 
δ 3.91 (3H, s), 6.82 (1H, s), 7.29 (1H, dd, J = 3.1, 9.1 Hz), 7.49-7.54 (4H, m), 7.60 
(1H, d, J = 3.1 Hz), 7.90-7.94 (2H, m).  13C NMR (100 MHz, CDCl3) δ 56.09, 
104.98, 107.00, 119.65, 123.96, 124.72, 126.38, 129.17, 131.17, 132.04, 151.24, 
157.15, 163.31, 178.45. 
O
O
O
O
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2’,2’-Dimethyl-2-(3,4-dimethoxyphenyloxy)methylpyrano[2,3-f]-chromen-4-one 
(134). The general procedure was used to afford 2.13 g of the title compound as a tan 
solid (37%). 1H NMR (400 MHz, CDCl3) δ 1.49 (6H, s), 3.85 (3H, s), 3.88 (3H, s), 
4.92 (2H, d, J = 0.7 Hz), 5.71 (1H, d, J = 10.0 Hz), 6.44 (1H, m), 6.47 (1H, dd, J = 
2.9, 8.8 Hz), 6.61 (1H, d, J = 2.8 Hz), 6.75 (1H, dd, J = 0.5, 10.0 Hz), 6.75-6.80 (1H, 
m), 6.84 (1H, dd, J = 0.5, 8.7 Hz) 7.95 (1H, d, J = 8.7 Hz).  13C NMR (100 MHz, 
CDCl3) δ 28.23 (2C), 56.02, 56.47, 66.85, 77.82, 101.40, 104.20, 109.32, 109.91, 
111.65, 114.99, 115.29, 117.90, 126.19, 130.49, 144.49, 150.09, 152.37, 152.39, 
157.61, 162.94, 177.46. IR (neat, NaCl): 2974, 1685, 1599, 1513, 1231, 1122 cm-1.  
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MP = 107-109 °C. HRMS (ESI+): m/z calc’d for C23H22NaO6, 417.1314; found 
417.1318. 
O
OOMe
 
5-Methoxy-2-(2-phenylethyl)chromone (141). The general procedure was used to 
afford 267 mg of the title compound as a brown oily solid (15%). 1H NMR (400 
MHz, CDCl3) δ 2.84-2.88 (2H, m), 3.01-3.05 (2H, m), 3.97 (3H, s), 6.05 (1H, s), 6.79 
(1H, d, J = 8.0 Hz), 6.98 (1H, dd, J = 0.88, 8.44 Hz), 7.19-7.23 (3H, m), 7.27-7.31 
(2H, m), 7.52 (1H, t, J = 8.36 Hz).  13C NMR (100 MHz, CDCl3) δ 32.95, 35.62, 
56.59, 106.37, 110.10, 111.91, 114.55, 126.66, 128.45, 128.77, 133.62, 139.97, 
158.69, 159.92, 166.01, 178.33. IR (neat, NaCl): 2932, 1657, 1604, 1475, 1386, 1265, 
1083 cm-1.  MP = 107-109 °C. HRMS (ESI+): m/z calc’d for C18H17O3, 281.1178; 
found 281.1182. 
O
OOH
 
5-Hydroxy-2-(2-phenylethyl)chromone (142). A BBr3 solution (1.0 M in CH2Cl2, 
200 µL, 0.20 mmol) was added dropwise into a solution of chromone 66 (42 mg, 0.15 
mmol) in CH2Cl2 (6 mL) at -78 ºC. The mixture was allowed to warm to room 
temperature. MeOH (1.0 mL) was added into the reaction flask to quench the reaction 
and the mixture was partitioned between H2O and CH2Cl2.  The organic phase was 
washed with H2O several times, dried over Na2SO4, and concentrated. The residue 
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was purified by flash chromatography (30% EtOAc in hexanes) as brown solid (26 
mg, 66%). The spectral data are consistent with those reported in the literature.107 1H 
NMR (400 MHz, CDCl3) δ 2.93 (2H, dd, J = 7.2, 8.1 Hz), 3.06 (2H, dd, J = 7.2, 8.1 
Hz), 6.07 (1H, s), 6.78 (1H, d, J = 8.2 Hz), 6.87 (1H, d, J = 8.36 Hz), 7.19-7.24 (3H, 
m), 7.30 (2H, dd, J = 7.2, 7.4 Hz), 7.50 (1H, t, J = 8.32 Hz), 12.52 (1H, s).  13C NMR 
(100 MHz, CDCl3) δ 33.00, 36.21, 106.97, 108.98, 110.73, 111.38, 126.80, 128.38, 
128.84, 135.29, 139.56, 156.86, 160.93, 169.94, 183.63. IR (neat, NaCl): 2925, 1655, 
1618, 1474, 1409, 1256, 847, 802 cm-1.  MP = 71-73 °C. HRMS (ESI+): m/z calc’d 
for C17H15O3, 267.1021; found 267.1021. 
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4.2.3 Chapter 3 
NEt2
MeO
MeO
OMe
O
 
N,N-Diethyl-3,4,5-trimethoxybenzamide (146).  A round bottom flask was charged 
with 3,4,5-trimethoxybenzoyl chloride (20 g, 86.7 mmol, 1 equiv) under ambient 
atmosphere and subsequently fitted with a rubber septum. The acid chloride was 
dissolved in 170 mL anhydrous CH2Cl2 and cooled with an ice-water bath. 
Diethylamine (18 mL, 173.4 mmol) was added over 10 min to the cooled solution and 
the reaction was warmed to room temperature overnight. The reaction was checked 
by TLC (20% hexanes in EtOAc) and indicated the absence of acid chloride.  The 
reaction mixture was diluted with 10% aq. HCl (50 mL) and transferred to a 
separatory funnel containing CH2Cl2 (150 mL) and 10% aq. HCl (150 mL). The 
layers were separated and the aqueous phase was extracted with CH2Cl2 twice.  The 
combined organic layers were washed with saturated NaHCO3 and the aqueous layer 
was extracted with CH2Cl2.  The combined organic layers were dried over Na2SO4, 
filtered, and concentrated on a rotary evaporator.  The residue was dissolved with a 
minimal amount of hot diethyl ether and allowed to stand at room temperature 
overnight. The resulting crystals were collected via suction filtration and washed with 
ice-cold diethyl ether and transferred to a round-bottomed flask and dried overnight to 
afford 13.4 g of pure amide as a white solid (57%).  The spectral data are consistent 
with those reported in the literature.139 1H NMR (400 MHz, CDCl3, 50 °C) δ 1.14 
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(6H, t, J = 7.0 Hz), 3.36 (4H, br s), 3.80 (3H, s), 3.81 (6H, s), 6.55 (2H, s). 13C NMR 
(100 MHz, CDCl3, 50 °C) δ 12.88, 14.31, 39.33, 43.33, 56.15, 60.81, 103.56, 132.64, 
138.63, 153.21, 170.90.  
H
MeO
MeO
OMe
O
 
3,4,5-Trimethoxybenzaldehyde (147).  A round bottom flask was charged with 
Cp2Zr(H)Cl (15.5 g, 60 mmol) under a nitrogen atmosphere and THF (60 mL) was 
added resulting in a cloudy, white suspension. Amide 146 (8 g, 30 mmol) in 30 mL 
THF was  added dropwise to the suspension over 10 min via syringe pump. Upon 
complete addition of amide, the slurry was allowed to stir for 15 minutes at room 
temperature.  The reaction was monitored by TLC (EtOAc) and demonstrated the 
absence of the amide 146. Silica gel (60 g) was added in one portion and the mixture 
was allowed to stir 5 min open to the atmosphere.  The heterogeneous solution was  
filtered eluting with Et2O. The filtrate was  poured into a separatory funnel containing 
H2O and Et2O.  The layers were separated and the aqueous phase was extracted with 
Et2O.  The combined organic extracts were dried over Na2SO4 and concentrated.  The 
crude aldehyde was purified by MPLC using silica gel (0-40% ethyl acetate in 
hexanes, 40 minutes, 254 nm) to give 5.81 g of pure aldehyde 147 as a white solid in 
99% yield. The spectral data are consistent with those reported in the literature.139 1H 
NMR (400 MHz, CDCl3) δ 3.92 (6H, s), 3.93 (3H, s), 7.12 (2H, s), 9.86 (1H, s). 13C 
NMR (100 MHz, CDCl3) 56.25, 60.99, 106.66, 131.72, 143.52, 153.63, 191.10. 
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O
NEt2
 
4-tert-Butyl-N,N-diethylbenzamide (148). The same procedure for the synthesis of 
amide 146 was used to afford 10.54 g of the title compound as a white solid (82%). 
The spectral data are consistent with those reported in the literature.140 1H NMR (400 
MHz, CDCl3, 50 °C) δ 1.16 (6H, m), 1.31 (9H, s), 3.40 (4H, br s), 7.27-7.30 (2H, m), 
7.36-7.39 (2H, m).  13C NMR (100 MHz, CDCl3, 50 °C) δ 12.88, 14.31, 39.33, 43.33, 
56.14, 60.81, 103.56, 132.64, 138.63, 153.21, 170.90. 
O
NEt2
Cl
Cl  
3,5-Dichloro-N,N-diethylbenzamide (149). The same procedure for the synthesis of 
amide 146 was used to afford 4.35 g of the title compound as a white solid (90%).141 
1H NMR (400 MHz, CDCl3) δ 1.06 (3H, br s), 1.17 (3H, br s), 3.18 (1H, m), 3.46 
(1H, m), 7.19 (2H, d, J = 1.9 Hz), 7.32 (1H, t, J = 1.9 Hz).  13C NMR (100 MHz, 
CDCl3) δ 12.76, 14.14, 39.47, 43.31, 124.80, 129.17, 135.21, 139.91, 168.09. 
O
NEt2
MeO2C  
Methyl 4-(Diethylcarbamoyl)benzoate (150). The same procedure for the synthesis 
of amide 146 was used to afford 5.88 g of the title compound as a colorless oil (99%). 
The spectral data are consistent with those reported in the literature.142 1H NMR (400 
MHz, CDCl3, 50 °C) δ 1.13 (6H, br s), 3.20 (2H, br s), 3.47 (2H, br s), 3.87 (3H, s), 
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7.38 (2H, d, J = 8.5 Hz), 8.01 (2H, d, J = 8.5 Hz).  13C NMR (100 MHz, CDCl3, 50 
°C) δ 12.86, 14.17, 39.32, 43.23, 52.25, 126.27, 129.77, 130.63, 141.57, 166.41, 
170.23. 
O
NEt2
 
N,N-Diethyl-1-naphthamide (151). The same procedure for the synthesis of amide 
146 was used to afford 16.10 g of the title compound as a yellow oil (90%). The 
spectral data are consistent with those reported in the literature.143 1H NMR (400 
MHz, CDCl3, 50 °C) δ 0.98 (3H, t, J = 7.1 Hz), 1.37 (3H, t, J = 7.1 Hz), 3.09 (2H, q, 
J = 6.86 Hz), 3.69 (2H, br s), 7.37-7.39 (1H, m), 7.43-7.52 (3H, m), 7.81-7.86 (3H, 
m).  13C NMR (100 MHz, CDCl3, 50 °C) δ 13.13, 14.31, 39.06, 43.14, 123.22, 
124.80, 125.17, 126.38, 126.89, 128.37, 128.77, 129.66, 133.51, 135.24, 170.31. 
NEt2
O
Br  
3-(4-Bromophenyl)-N,N-diethylpropanamide (152). To a stirring solution of 
commercially available 3-(4-bromophenyl)propanoic acid (4.51 g, 19.6 mmol) in 
CH2Cl2 (40 mL) cooled to 0 °C were EDCI (4.12 g, 21.6 mmol), and added 
diethylamine (4.50 mL, 43.2 mmol) in sequence and the reaction was allowed to 
warm to room temperature overnight.  The reaction mixture was transferred to a 
separatory funnel containing 10% aq. HCl and CH2Cl2.  The layers were separated 
and the aqueous layer was extracted twice more with CH2Cl2.  The combined organic 
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layers were washed with saturated aq. NaHCO3; the layers were separated and the 
aqueous layers were extracted with CH2Cl2.  The combined organic layers were dried 
over Na2SO4, concentrated, and purified by MPLC on silica gel (0-50% ethyl acetate 
in hexanes, 50 min, 254 nm) to give 2.64 g of the title compound as a white solid 
(47%). The spectral data are consistent with those reported in the literature.144 1H 
NMR (400 MHz, CDCl3) δ 1.10 (6H, t, J = 7.1 Hz), 2.54-2.58 (2H, m), 2.91-2.95 
(2H, m), 3.22 (2H, q, J = 7.1 Hz), 3.37 (2H, q, J = 7.1 Hz), 7.01 (2H, m), 7.38-7.40 
(2H, m). 13C NMR (100 MHz, CDCl3,) δ 13.23, 14.43, 31.05, 34.87, 40.39, 42.02, 
119.94, 130.43 (2C), 131.60 (2C), 140.73, 170.95). 
O
H
 
4-tert-Butylbenzaldehyde (153). The same procedure for the synthesis of aldehyde 
147 was used to afford 2.92 g of the title compounds as a colorless oil (90%). The 
spectral data are consistent with those reported in the literature.145 1H NMR (400 
MHz, CDCl3, rotamers) δ 1.31 (9H, m), 7.50-.52 (2H, m), 7.76 (2H, m), 9.94 (1H, 
m).  13C NMR (100 MHz, CDCl3, rotamers) 31.01, 35.27, 125.93, 129.63, 134.09, 
158.31, 191.84. 
O
Cl
Cl
H
 
3,5-Dichlorobenzaldehyde (154). The same procedure for the synthesis of aldehyde 
147 was used to afford 1.75 g of the title compounds as a yellow solid (92%). The 
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spectral data are consistent with those reported in the literature.145 1H NMR (400 
MHz, CDCl3) δ 7.57 (1H, t, J = 1.9 Hz), 7.72 (2H, d, J =1.9 Hz), 9.91 (1H, s).  13C 
NMR (100 MHz, CDCl3) 127.88, 134.15, 136.26, 138.58, 189.44. 
O
H
MeO2C  
Methyl 4-Formylbenzoate (155). The same procedure for the synthesis of aldehyde 
147 was used to afford 1.83 g of the title compounds as a yellow solid (93%). The 
spectral data are consistent with those reported in the literature.145 1H NMR (400 
MHz, CDCl3) δ  3.89 (3H, s), 7.87-7.89 (2H, m), 8.11 (2H, d, J = 8.2 Hz), 10.03 (1H, 
s).  13C NMR (100 MHz, CDCl3) 52.54, 129.47, 130.13, 134.99, 139.09, 165.97, 
191.65. 
O
H
 
1-Naphthaldehyde (156). The same procedure for the synthesis of aldehyde 147 was 
used to afford 1.10 g of the title compounds as yellow oil (97%). The spectral data are 
consistent with those reported in the literature.132 1H NMR (400 MHz, CDCl3) δ  
7.58-7.66 (2H, m), 7.68-7.72 (1H, m), 7.93 (1H, d, J = 8.2 Hz), 8.00 (1H, d, J = 7.0 
Hz), 8.11 (1H, d, J = 8.2 Hz), 9.26 (1H, d, J = 8.6 Hz), 10.41 (1H, s). 13C NMR (100 
MHz, CDCl3) 125.03 (2C), 127.12, 128.62, 129.23, 130.67, 131.54, 133.86, 135.46, 
136.87, 193.73. 
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H
O
Br  
3-(4-Bromophenyl)propanal (157). The same procedure for the synthesis of 
aldehyde 147 was used to afford 449 mg of the title compounds as colorless oil 
(85%). The spectral data are consistent with those reported in the literature.146 1H 
NMR (400 MHz, CDCl3) δ  2.67-2.71 (2H, m), 2.82-2.85  (2H, t, J = 7.4 Hz), 7.01-
7.03 (2H, m), 7.32-7.35 (2H, m), 9.71-9.72 (1H, m). 13C NMR (100 MHz, CDCl3) 
27.23, 44.71, 119.76, 129.99 (2C), 131.37 (2C), 139.34, 200.80. 
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